Strain	AltDE	AltDE1

Total genes in the genome	4389	4748

Total core genes in the genome (%)a	3631 (83)	3631 (76)

Total flexible genes in the genome (%)a	758 (17)	1117 (24)

Comparison	Temperature (13-25°C)	Media (RM-MMG)	Media (MMG-STR)	Temperature (13-25°C)	Media (RM-MMG)	Media (MMG-STR)

Total genes differentially expressed (%)a	985 (22)	1037 (24)	1627 (37)	1026 (22)	1362 (29)	2771 (58)

Total core genes differentially expressed (%)b	763 (21)	809 (22)	1286 (35)	684 (19)	978 (27)	2143 (59)

Contribution of core genes to total genes differentially expressed	77%	78%	79%	67%	72%	77%

Total flexible genes differentially expressed (%)c	222 (29)	230 (30)	342 (45)	342 (30)	384 (34)	629 (56)

Contribution of flexible genes to total genes differentially expressed	23%	22%	21%	33%	28%	23%


Method

Robetta

FOLDEF

KFC

MINERVA

APIS (this work)


Food (utensil)	Accuracy

Meat (fork and knife)	127%

Sides (fork)	82.6%

Soup (spoon)	60.2%

Pizza (hands)	87.3%

Soda (hands)	81.7%

Smoothie (straw)	57.7%

Total	81.2%

Food (utensil)

Meat (fork and knife)

Sides (fork)

Soup (spoon)

Pizza (hands)

Soda (hands)

Smoothie (straw)

Total


	Unst. est.	SE	St. est.	CR

Harsh discipline

 Physical discipline	1.37	0.30	.82	4.63***

 Emotional discipline	1.00	-	.70	-

Internalizing problems

 Harsh discipline	1.45	0.33	.50	4.35***

 Emotional symptoms (SDQ)	1.00	-	.62	-

 Peer problems (SDQ)	0.52	0.09	.45	5.64***

 Depressive symptoms (CDI)	1.91	0.32	.61	5.99***

Working memory

 Harsh discipline	−2.23	2.19	-.08	−1.02

 Block-Tapping test forward	1.00	-	.83	-

 Block-Tapping test backward	0.92	0.20	.71	4.59***

School performance

 Harsh discipline	−0.01	0.09	-.01	−0.12

 Working memory	0.01	0.03	.31	3.80***

 School grades English	1.22	0.11	.74	10.97***

 School grades Mathematics	1.14	0.11	.70	10.56***

 School grades Swahili	1.00	-	.61	-

 School grades Science	1.35	0.12	.83	11.51***

	Unst. est.	SE	St. est.	CR

Working memory

Harsh discipline	−2.23	2.19	-.08	−1.02

Block-Tapping test forward	1.00	-	.83	-

Block-Tapping test backward	0.92	0.20	.71	4.59***

School performance

Harsh discipline	−0.01	0.09	-.01	−0.12

Working memory	0.01	0.03	.31	3.80***

School grades English	1.22	0.11	.74	10.97***

School grades Mathematics	1.14	0.11	.70	10.56***

School grades Swahili	1.00	-	.61	-

School grades Science	1.35	0.12	.83	11.51***


Factor	Chi-square	Significance

Female sex	255.97	p. < 0.01

Family history of osteoporosis	3.11	p. < 0.01

Previous fracture	1.51	p. < 0.01

Underweight	20.04	p. < 0.01

Steroids	7.21	p. < 0.05

Rheumatoid Arthritis	2.86	ns

Nephrolithiasis*	3.00	ns

Thyroid*	3.85	ns

Early menopause	47.36	p. < 0.01

Amenorrhea > 12 months	0.15	ns

Ovariectomy by age 50	44.61	p. < 0.01

Alcohol consumption	0.11	ns

Smoking habit	6.18	p. < 0.05

Exercise < 30 min/day	0.17	ns

Avoiding dairy products	10.50	p. < 0.01

Exposure to sunlight	8.85	p. < 0.05

Crohn disease*	0.74	ns

Celiac disease*	0.31	ns

Rectocolitis ulcerosa*	0.40	ns

Secondary osteoporosis*	15.20	p. < 0.01


	Telencephalon	Opctic tecta	Cerebellum	Medulla	Hypothalamus

Olfactory bulbs	1.06	1.02	1.23	1.15	1.04

Telencephalon		0.96	1.16	1.08	0.98

Optic tecta			1.21	1.13	1.03

Cerebellum				0.93	0.85

Medulla					0.91

Olfactory bulbs

Telencephalon

Optic tecta

Cerebellum

Medulla


Variable	Odds ratio	95% confidence interval

Sex

 Male	1.00	—

 Female	2.93	1.29–6.67

Posttest HIV counselling

 No	1.00	—

 Yes	2.96	1.22–7.19

Used contraception to prevent risk of transmission of HIV to partner

 No	1.00	—

 Yes	2.30	1.01–5.20

Used contraception due to partner's preference

 No	1.00	—

 Yes	2.76	1.08–7.06

Last CD4 cell count (per increase of 50 cells/mL)	0.73	0.62–0.87


	European Americans	African Americans	Mexican Americans

	With noise (%)	Denoised (%)	With noise (%)	Denoised (%)	With noise (%)	Denoised (%)

Europe	100	100	97	94	100	98

Africa	1	0	99	99	91	80

America	29	7	32	10	100	100

East Asia	1	0	20	4	76	27

Oceania	6	0	10	3	18	0

Central Asia	11	1	30	3	38	7

	European Americans	African Americans

	With noise (%)	Denoised (%)	With noise (%)

Europe	100	100	97

Africa	1	0	99

America	29	7	32

East Asia	1	0	20

Oceania	6	0	10

Central Asia	11	1	30

African Americans	Mexican Americans

Denoised (%)	With noise (%)	Denoised (%)

94	100	98

99	91	80

10	100	100

4	76	27

3	18	0

3	38	7


f	1/2	5/8	3/4	7/8	1

model A: simple	69	59	47	32	16

model B: treated class	62	53	42	31	19

model C: day care	80	73	62	43	20

model E: dual transmission	79	71	61	47	29

f	1/2	5/8	3/4	7/8	1

model A: simple	69	59	47	32	16

model B: treated class	62	53	42	31	19

model C: day care	80	73	62	43	20

model E: dual t		7		4	2


Variables	PITC acceptance status

Yes (%)

Age

≤19	85 (81.7)

20–29	181 (81.9)

30–45	46 (75.4)

Residence

Urban	235 (78.9)

Rural	77 (87.5)

Religion

Orthodox christians	130 (78.8)

Muslim	137 (82.0)

Protestant	40 (81.6)

Catholic	5 (100)

Ethnicity

Berta	78 (87.6)

Amhara	133 (76.0)

Oromo	53 (81.5)

Othersa	48 (84.2)

Educational status

Not able to read and write	37 (78.7)

Able to read and write	31 (77.5)

Grade 1–8	70 (79.5)

Grade 9–12	72 (76.6)

Above 12	102 (87.2)

Occupation

Merchant	29 (90.6)

Farmer	49 (84.5)

Employedb	105 (85.4)

Student	25 (89.3)

Housewife	104 (71.7)

Marital status

Unmarried	8 (66.7)

Married/living together	303 (83.2)

Divorced	1 (33.3)

Household expenditur (Birr/month)

No response	78 (81.2)

<1000	70 (83.7)

≥1000	164 (74.5)


Week	Direct heritability	Indirect heritability	Total heritability

1	0.17 (0.03)	0.44 (0.13)	0.19 (0.10)


Amino acid	No. residues/100 residues

Arginine	7.12

Histidine	3.39

Isoleucine	3.76

Leucine	7.71

Lysine	9.18

Methionine	3.52

Phenylalanine	4.46

Threonine	4.67

Tryptophan	0.19

Valine	5.17

Indispensable AA (IAA)	49.16

Alanine	5.70

Aspartic acid	10.45

Cystine	1.05

Glutamic acid	15.72

Glycine	6.56

Proline	3.61

Serine	4.10

Tyrosine	3.65

Dispensable AA (DAA)	50.84


Anatomical region	BA	x	y	z	Z-value	Extent

R lingual/paraH gyrus	19/30	18	−51	−3	5.03	109

R lingual gyrus	19	18	−59	−5	3.54

L lingual/paraH gyrus	19/30	−16	−47	−3	4.91	227

		−8	−62	0	3.50

L post. cingulate gyrus	23/31	−12	−56	12	3.50

Lingual gyrus	19/18	4	−58	1	3.63	16

R posterior insula/TTG	41	38	−17	16	4.49	45

L superior temporal gyrus	22	−50	−24	16	4.07	38

L MidFG/frontal pole	10	−34	51	16	4.00	21

L mPFC/ACC	10	−8	43	14	3.97	17

L anterior cingulate cortex	32	−14	34	19	3.87	20

		−22	36	15	3.18

Anterior cingulate cortex	32/24	0	47	0	3.39	14

L inferior frontal gyrus	44/45	−34	11	16	3.85	16

mPFC/frontal pole	10	−4	65	12	3.85	11

R MidFG/frontal pole	10	40	47	12	3.63	15

L precuneus	7	−16	−76	42	4.42	78

L posterior cingulate	31	−12	−33	31	4.19	13

R precuneus	7	12	−72	40	3.76	44

		14	−62	42	3.60

		12	−68	48	3.35

Cuneus	17/31	0	−71	11	3.44	10

Precuneus/post. cingulate	31/23	−2	−63	25	3.37	41

	31/23	−2	−68	33	3.35

R IPL/angular g./TPJ	40/39	40	−62	38	3.71	25

		34	−68	42	3.33

L MTG/angular g./TPJ	39	−34	−65	29	3.71	22

L IPL/angular g./TPJ	40/39	−51	−60	40	3.65	17

R hippocampus/ParaH g.	30/19	24	−39	−6	3.65	26

L superior temporal gyrus	22/42	−61	−26	16	3.59	15

Anatomical region	BA	x	y	z	Z-value	Extent

				42	3.33

L MTG/angular g./TPJ	39	−34	−65	29	3.71	22

L IPL/angular g./TPJ	40/39	−51	−60	40	3.65	17

R hippocampus/ParaH g.	30/19	24	−39	−6	3.65	26

L superior temporal gyrus	22/42	−61	−26	16	3.59	15


Dataset	Number of sequences

GATA1	14,351

SOX2	4526

OCT4	3761

STAT3	2546

KLF1	945

Dataset	Number of sequences

OCT4	3761

STAT3	2546

KLF1	945


Variables	Group 1 ISH positiveN = 10	Group 2 ISH negative N = 15	P

Patient age at LT	49 ±11	52 ±11	.66

Female gender (patient)	40%	13%	.13

Caucasian (patient)	90%	87%	.69

Recipient body mass index	31 ±7	29 ±6	.51

MELD at LT	14 ±5	18 ±9	.42

Genotype 1 (unknown in 1 patient per group)	56%	86%	.11

Donor age	47 ±13	43 ±14	.82

Female gender (donor)	40%	53%	.51

Caucasian (Donor)	90%	67%	.34

Cold ischemia time, hours	7 ±2	7 ±2	.74

Warm ischemia time, minutes	39 ±9	34 ±10	.28

Tacrolimus as primary immune suppressant	100%	83%	.23

Steroid bolus treated ACR	30%	40%	.61

LT to ISH biopsy interval, months	23 ±10	24 ±12	.91


Experiment	∆6	REG19	TS01

average	133	6200	42,633


Pin	I/O Attached	Action	States

L0	Red LED	move

L1	Green LED	turn

L2	Orange LED		gripper is open

L4	Yellow LED	bottle is collected

L3	Switch A	touching

L5	Switch B	see drop

L6	Switch C	see bottle

L7	Switch D	over drop

Pin	I/O Attached	Action	States

L0	Red LED	move

L1	Green LED	turn

L2	Orange LED		gripper is open

L4	Yellow LED	bottle is collected

L3	Switch A	touching

L	Switc	see drop

5	h B

L6	Switch C	see bottle

L7	Switch D	over drop


	age (median, IQR)	Female sex (n)	FEV1 % predicted (median, IQR)	ICS dose, mcg/day (median, IQR)	Current smoker (n)

AKL1 – Pla	41.00,	13	90.00, 	1000, 400 – 2000


Ancestry	Parent	Count	Mean age

		Alive	Dead	Total	Alive	Dead	All


Pathway	miRNAs	Genes

MAPK signaling pathway	10	95

PI3K-Akt signaling pathway	9	106

Endocytosis	10	72

TGF-β signaling pathway	6	35

Wnt signaling pathway	9	58

Ubiquitin mediated proteolysis	8	49

Regulation of actin cytoskeleton	8	74

Pathway	miRNAs	Genes

PI3K-Akt signaling pathway	9	106

Endocytosis	10	72

TGF-β signaling pathway	6	35

Wnt signaling pathway	9	58

Ubiquitin mediated proteolysis	8	49

Regulation of actin cytoskeleton	8	74


Gene	GeneBank accession number	Specific primer sequences (5’ to 3’)	Product size (bp)

αA-crystallin (CRYAA)	U05569	F: CGGGACAAGTTCGTCATCTT	203

 	 	R: GCAGACAGGGAGCAAGAGAG

Heat-shock protein 70 (Hsp70)	NM05345	1F: AAGTACAAAGCGGAGGACG	249

 	 	1R: GATGGGGTTACACACCTGC

 	 	2F: TGCTGATCCAGGTGTACGAG	185

 	 	2R: CGTTGGTGATGGTGATCTTG

Heat-shock protein 90α (Hsp90α))	NM005348.3	F: ACCCAGACCCAAGACCAACCG	141

 	 	R: ATTTGAAATGAGCTCTCTCAG

Superoxide dismutase (SOD)	NM000454.4	F: AGGGCATCATCAATTTCGAGC	430

 	 	R: CAAGGGAATGTTTATTGGGCG

αB-crystallin (CRYAB)	NM001885.1	F: TCACCTAGCCACCATGGACATCGCCA	541

 	 	R: CAAAAGCTTATTACTATTTCTTGGGGG

Metallothionein 1M (MT)	NM176870.2	F: GCAAAGAGTGCAAATGCACCTC	125

 	 	R: TCAGGCACAGCAGCTGCACT

Interleukin-6 (IL-6)	NM000600.2	F: CTGGTCTTTTGGAGTTTGAGGTATACC	295

 	 	R: CCATGCTACATTTGCCGAAGA

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	BC014085	F: GAAGGTGAAGGTCGGAGT	225

 	 	R: GAAGATGGTGATGGGATTTC

Gene	GeneBank accession number	Specific primer sequences (5’ to 3’)	Product size (bp)

αB-crystallin (CRYAB)	NM001885.1	F: TCACCTAGCCACCATGGACATCGCCA	541

		R: CAAAAGCTTATTACTATTTCTTGGGGG

Metallothionein 1M (MT)	NM176870.2	F: GCAAAGAGTGCAAATGCACCTC	125

		R: TCAGGCACAGCAGCTGCACT

Interleukin-6 (IL-6)	NM000600.2	F: CTGGTCTTTTGGAGTTTGAGGTATACC	295

		R: CCATGCTACATTTGCCGAAGA

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	BC014085	F: GAAGGTGAAGGTCGGAGT	225

		R: GAAGATGGTGATGGGATTTC


Characteristic	Doctors	Nurses

Sex

Female	7	5

Male	8	0

Age (years)

Mean	37	45

Range	26–53	38–53

Years of practice in total

Mean	13	24

Range	1.75–29	16–33

Years of practice in nephrology

Mean	9	20

Range	0.3–26	15–26


	Pre-Delphi questionnaire	Round 1	Round 2	Round 3

Consumers	16	13	13	9

Carers	3	2	0	0

Professionals	26	21	17	16

	Pre-Delphi questionnaire	Round 1	Round 2

Consumers	16	13	13

Carers	3	2	0

Professionals	26	21	17


Exposure	Cases (n = 2634)	Controls (n = 5074)	Crude OR (95%CI)	Adjusted OR† (95%CI)

Current use, n (%)

Conventional NSAIDs − P	1599 (60.7)	3013 (59.


	Compound	Content (mg/g)

Panax ginseng	Rb1	2.24

Re	1.13

Rg1	1.47

Salvia miltiorrhiza	Salvianolia acid B	28.2

Tanshinone IIA	0.6

	Compound	Content (mg/g)

Salvia miltiorrhiza	Salvianolia acid B	28.2

Tanshinone IIA	0.6


Group	Mean fluorescence recovery rate(%,x±s) (t=4min)

BGC-823Cx43	35.6±0.9*

BGC-823Cx43T154A	12.1±0.6

Group	Mean fluorescence recovery rate(%,x±s) (t=4min)

BGC-823v	13.4±0.7

SGC-7901Cx43	39.4±0.8†

SGC-7901Cx43T154A	15.3±0.4

SGC-7901v	14.7±0.6


	b

Dominance

Intercept	−0.30

SS vs. LL + LS	0.05

Sex	0.70

SS vs. LL + LS × sex	−0.15

Conscientiousness

Intercept	0.55

SS vs. LL + LS	−0.46

Sex	−0.62

SS vs. LL + LS × sex	0.22

Low alpha

Intercept	−0.47

SS vs. LL + LS	0.31

Sex	0.77

SS vs. LL + LS × sex	−0.30

Disinhibition

Intercept	−0.47

SS vs. LL + LS	0.41

Sex	0.65

SS vs. LL + LS × sex	−0.33

Negative emotionality/low dominance

Intercept	0.21

SS vs. LL + LS	0.03

Sex	−0.62

SS vs. LL + LS × sex	0.12


	Categories of Infant Feeding Index	ptrend

Poor	Medium	Good

Acute upper


		Factor solution OLQ-13	Factor solution OLQ-11

item	dim	1	2	3	1	2	3

A	Me	-	-	.408	-	-	.405

B	Co	-	.753	-

	M		.88	-		.6


Parameter	Total (N = 193)

Reason for last admission

 Palliative procedure or surgery	28 (14.5)

 Gastrointestinal symptoms	52 (26.9)

 Cardiovascular or pulmonary symptoms	39 (20.2)

 Infectious state	31 (16.2)

 Uncontrolled pain	11 (5.7)

 Hematologic instability	12 (6.2)

 Neurologic symptom	7 (3.6)

 Others	13 (6.7)

ICU admission in the last month	23 (11.9)

Imaging examination conducted in the last month

 No examination	56 (29.0)

 Examination	137 (71.0)

CT	101 (73.7)

MRI	8 (5.8)

PET-CT	1 (0.7)

Combined imaging (>2)	27 (19.7)

Type of treatment administered during the last 6 mo

 Chemotherapy alone	155 (80.3)

 Chemotherapy with radiation	26 (13.5)

 Chemotherapy with surgery	12 (6.2)

Gastrointestinal surgery	9

Pelvic exenteration	2

Neuro-surgery	1

Type of chemotherapy-agent administered during the last 6 mo

 IV only	177 (91.7)

 IV with PO	16 (8.3)

Parameter

Reason for last admission

Palliative procedure or surgery

Gastrointestinal symptoms

Cardiovascular or pulmonary symptoms

Infectious state

Uncontrolled pain

Hematologic instability

Neurologic symptom

Others

ICU admission in the last month

Imaging examination conducted in the last month

No examination

Examination

CT

MRI

PET-CT

Combined imaging (>2)

Type of treatment administered during the last 6 mo

Chemotherapy alone

Chemotherapy with radiation

Chemotherapy with surgery

Gastrointestinal surgery

Pelvic exenteration

Neuro-surgery

Type of chemotherapy-agent administered during the last 6 mo

IV only

IV with PO


Assembler	Species assembled

A.hydrophila	B.cereus	B.fragilis	S.aureus	X.axonopodis

SGA	68.8	23.4	41.2	38.1	47.8

SOAPdenovo	243.9	57.9	116.1	146.3	74.2

SPAdes	379.7	97.2	157.7	187.1	117.5

Velvet	184.4	38.9	125.2	122.5	83.0


Element	Measurement

Ulna (NMMNH P-19460), length of semilunar notch	24.5*

Ulna (NMMNH P-19460), depth of semilunar notch	6.2*

Ulna (NMMNH P-19460), maximum mediolateral breadth	21.5

Radius (NMMNH P-19460), length	93.0

Radius (NMMNH P-19460), anteroposterior midshaft diameter	11.0

Radius (NMMNH P-19460), midshaft mediolateral diameter	11.5

Metacarpal II (NMMNH P-19460), length	25.0

Metacarpal II (NMMNH P-19460), proximal breadth	9.8

Metacarpal II (NMMNH P-19460), midshaft mediolateral diameter	8.7

Metacarpal II (NMMNH P-19460), distal breadth	12.4

Metacarpal III (NMMNH P-19640), length	29.3

Metacarpal III (NMMNH P-19640), proximal breadth	13.9

Metacarpal III (NMMNH P-19640), midshaft mediolateral diameter	9.8

Metacarpal III (NMMNH P-19640), distal breadth	13.5

Metacarpal IV (NMMNH P-19640), length	23.9

Metacarpal IV (NMMNH P-19640), proximal breadth	10.9

Metacarpal IV (NMMNH P-19640), midshaft mediolateral diameter	6.8

Metacarpal IV (NMMNH P-19640), distal breadth	9.9

Ungual (NMMNH P-19640), proximal breadth of most complete	8.6

Element	Measurement

Metacarpal IV (NMMNH P-19640), distal breadth	9.9

Ungual (NMMNH P-19640), proximal breadth of most complete	8.6


	Media surveillance	Active surveillance	Total casualties

	Jan 08 –S	Oct


First author	Year	Skin condition

Praveenkumar et al. [29]	2016	Psoriasis

Kokpol et al. [30]	2014	Psoriasis

Henseler et al. [31]	1995	Psoriasis

Owczarczyk-Saczonek et al. [34]	2015	Psoriasis

Gisondi et al. [26]	2007	Psoriasis

Nagpal et al. [51]	2016	Acne

Del Prete et al. [52]	2012	Acne

Akin Belli et al. [54]	2016	Rosacea

Shlyankevich et al. [56]	2014	Hidradenitis suppurativa

Banger et al. [61]	2015	Androgenic alopecia

El Sayed et al. [62]	2016	Androgenic alopecia

Saleh et al. [66]	2014	Lichen planus

Arias-Santiago et al. [65]	2011	Lichen planus

Lee et al. [68]	2017	Atopic dermatitis

Ambiel et al. [71]	2014	Pemphigus

Saylam Kurtipek et al. [83]	2015	Holoderma

Wali et al. [84]	2016	Striae

Chen et al. [85]	2016	Acanthosis nigricans

Puttegowda et al. [75]	2015	Tendon xanthomas

Nagase et al. [76]	2013	Skin aging

Penington et al. [86]	2007	Wound healing


MIGS ID	Property	Term	Evidence codea

		Domain Bacteria	TAS [13]

		Phylum Bacteroidetes	TAS [14,15]

		Class Bacteroidia	TAS [14,16]

	Current classification	Order Bacteroidales	TAS [14,17]

		Family Rikenellaceae	TAS [14,18]

		Genus Alistipes	TAS [5,19]

		Species Alistipes timonensis	IDA

		Type strain JC136T	IDA

	Gram stain	Negative	IDA

	Cell shape	Bacilli	IDA

	Motility	Nonmotile	IDA

	Sporulation	Nonsporulating	IDA

	Temperature range	Mesophile	IDA

	Optimum temperature	37°C	IDA

MIGS-6.3	Salinity	Growth in BHI medium + 1% NaCl	IDA

MIGS-22	Oxygen requirement	Anaerobic	IDA

	Carbon source	Unknown	NAS

	Energy source	Unknown	NAS

MIGS-6	Habitat	Human gut	IDA

MIGS-15	Biotic relationship	Free living	IDA

MIGS-14	PathogenicityBiosafety levelIsolation	Unknown2Human feces	NAS

MIGS-4	Geographic location	Senegal	IDA

MIGS-5	Sample collection time	September 2010	IDA

MIGS-4.1	Latitude	13.7167	IDA

MIGS-4.1	Longitude	16.4167	IDA

MIGS-4.3	Depth	Surface	IDA

MIGS-4.4	Altitude	51 m above sea level	IDA


 	Correct reactions	Correct

 	(ignoring enzyme)	(including enzyme)

Pantothenate and coenzyme A biosynthesis pathway

Recall(P) (%)	78 (7/9)	56 (5/9)

Precision (%)	59 (24/41)	41 (17/41)

Tetrahydrofolate biosynthesis pathway

Recall(P) (%)	90 (9/10)	70 (7/10)

Precision (%)	60 (39/65)	38 (25/65)

Aerobic fatty acid β-oxidation I pathway

Recall(P) (%)	29 (2/7)	29 (2/7)

Precision (%)	30 (11/37)	14 (5/37)

	Correct reactions	Correct

	(ignoring enzyme)	(including enzyme)

Pantothenate and coenzyme A biosynthesis pathway

Recall(P) (%)	78 (7/9)	56 (5/9)

Precision (%)	59 (24/41)	41 (17/41)

Tetrahydrofolate biosynthesis pathway

Recall(P) (%)	90 (9/10)	70 (7/10)

Precision (%)	60 (39/65)	38 (25/65)

Aerobic fatty acid β-oxidation I pathway

Rec	29 	29 (

	Correct reactions	Correct

	(ignoring enzyme)	(including enzyme)

all(P) (%)	(2/7)	2/7)

Precision (%)	30 (11/37)	14 (5/37)


Prognosis	Wald	P	Exp(B)	95% CI for Exp(B)

Lower	Upper


Year	Zonal Population*	New PTB+ cases Reported (n = 8558)	Case Notification/ 105 persons/year	Proportion of estimated PTB+ incident cases notified, %**

1994	1004000	512	49	45.2

1995	1070160	1025	96	87.9

1996	1101195	1162	106	96.8


	Intervention (n=5297)	Control (n=5246)	Incidence rate ratio (95% CI)	p value

Number of events	Incidence rate (cases per 100 child-years, 95% CI)	Number of events	Incidence rate (cases per 100 child-years, 95% CI)

Other	36	0·45 (0·30–0·60)	36	0·45 (0·30–0·59)	1·02 (0·62–1·66)	0·94

Total	318	3·99 (3·55–4·43)	278	3·45 (3·05–3·86)	1·15 (0·95–1·38)	0·15


Folates	Methionine cycle	Transsulfuration	Other

THF = 4.61	Met = 49.2	Cysta = 36.9	Ser = 563

510CH = 0.28	SAM = 81.1	Cys = 195	Gly = 924

510CH2 = 0.51	SAH = 19.1	GluCys = 9.8	Sarc = 9.16

10fTHF = 3.41	Hcy = 1.12	GSH = 6591	DMG = 0.71

5mTHF = 4.50		GSSG = 61.3	Aicart = 0.94

DHF = 0.039		Glut = 3219	HCOOH = 13.1


Experimental phase	Correlation	Brain regions	x	y	z	Cluster size	t value	p value FWE

Fear conditioning	Positive	Posterior cingulate cortex	12	−34	46	70	3.10	0.033

Posterior insular cortex	44	−38	24	116	3.22	0.034

Amygdala	16	2	12	140	3.32	0.037

Hypothalamus	−12	0	−8	33	2.71	0.039

Anterior insular cortex	36	28	6	138	3.09	0.051

Negative	Orbitofrontal cortex	−16	34	−24	21	3.21	0.038

Subgenual anterior cingulate cortex	−6	18	−18	48	3.00	0.039

Shock delivery (unconditioned responses)	Positive	Hypothalamus	8	4	−32	357	4.11	0.015

Middle insular cortex	−40	2	8	311	3.53	0.040

Negative	Orbitofrontal cortex	−14	34	−18	44	3.40	0.011

Late extinction learning	Positive	Subgenual anterior cingulate cortex	−14	26	−14	30	2.88	0.028

Negative	Middle insular cortex	−36	4	16	62	3.27	0.024

Early extinction recall	Positive	Parahippocampus	−30	2	−20	183	5.35	0.001

Subgenual anterior cingulate cortex	10	12	−18	64	4.39	0.002

Anterior insular cortex	32	18	12	82	4.35	0.003

Anterior insular cortex	−62	10	0	1595	5.34	0.005

Dorsal anterior cingulate cortex	10	24	40	91	4.13	0.005

Ventromedial prefrontal cortex	−14	40	−26	572	4.37	0.014

Middle cingulate cortex	−4	0	36	76	3.33	0.024

Orbitofrontal cortex	−16	52	−18	572	3.94	0.034

Experimental phase	Correlation	Brain regions	x	y	z	Cluster size	t value

Fear conditioning	Positive	Posterior cingulate cortex	12	−34	46	70	3.10

Posterior insular cortex	44	−38	24	116	3.22

Amygdala	16	2	12	140	3.32

Hypothalamus	−12	0	−8	33	2.71

Anterior insular cortex	36	28	6	138	3.09

Negative	Orbitofrontal cortex	−16	34	−24	21	3.21

Subgenual anterior cingulate cortex	−6	18	−18	48	3.00

Shock delivery (unconditioned responses)	Positive	Hypothalamus	8	4	−32	357	4.11

Middle insular cortex	−40	2	8	311	3.53

Negative	Orbitofrontal cortex	−14	34	−18	44	3.40

Late extinction learning	Positive	Subgenual anterior cingulate cortex	−14	26	−14	30	2.88

Negative	Middle insular cortex	−36	4	16	62	3.27

Early extinction recall	Positive	Parahippocampus	−30	2	−20	183	5.35

Subgenual anterior cingulate cortex	10	12	−18	64	4.39

Anterior insular cortex	32	18	12	82	4.35

Anterior insular cortex	−62	10	0	1595	5.34

Dorsal anterior cingulate cortex	10	24	40	91	4.13

Ventromedial prefrontal cortex	−14	40	−26	572	4.37

Middle cingulate cortex	−4	0	36	76	3.33

Orbitofrontal cortex	−16	52	−18	572	3.94


	ANXA1-SER

	HPV+	HPV-	Controls

Cancer	13.5 ± 1.6	14.6 ± 0.4	-

Epithelium	23.2 ± 1.7*	16.0 ± 1.0	15.3 ± 0.3


Variations		1st Day	2nd Day	3rd Day	P value

Number of bolusesrequired	Group B	31.47±24.39	24.07±20.25	19.20±14.59	0.084

Group L	38.87±28.27	21.13±16.82	17.77±12.38

Number of bolusesdelivered	Group B	15.87±6.66	9.97±4.79	8.93±3.95	0.348


Reference	Measurement of PAH-RPF/true RPF (n/n)	PAH-RPF (ml/min)	True RPF (ml/min)

[17]	6 (0)	-	690

[18]	40 (11)	475	1116

[19]	22 (6)	474	1238


	accepted marine species in WORMS	18S V9 OTUs in planktona

Acanthocephala	468	0

Annelida	12 862	404 (48)

Arthropoda	57 871	9497 (205)

Brachiopoda	396	8 (4)

Bryozoa	6167	15 (5)

Cephalorhyncha	238	13

Chaetognatha	131	531 (7)

Chordata	22 248	6972 (32)

Cnidaria	11 407	842 (82)

Ctenophora	192	33 (9)

Cycliophora	2	0

Dicyemida	122	1

Echinodermata	7252	74 (19)

Entoprocta	180	12

Gastrotricha	497	2

Gnathostomulida	98	0

Hemichordata	130	12 (3)

Mollusca	45 219	560 (89)

Nematoda	7152	30 (6)

Nemertea	1359	81 (4)

Orthonectida	25	0

Phoronida	19	0

Placozoa	1	0

Platyhelminthes	12 230	148 (12)

Porifera	8476	25 (4)

Rotifera	187	7 (2)

Sipuncula	147	0

Tardigrada	193	2

Xenacoelomorpha	433	0

unassigned metazoan	n.a.	402

total	195 702	19 671 (531)


	CON	HSD2BKO

Hsd11b1 (E17.5; norm to HPRT)	0.188 ± 0.028	0.148 ± 0.022

Plasma corticosterone (nmol/l)

Fetal (E17.5)	31.2 ± 2.1	28.1 ± 2.0

Adult	(10)	(9)

AM	35.3 ± 4.8	34.3 ± 6.7

PM	196.5 ± 16.6	179.9 ± 22.9

Restraint stress corticosterone levels (nmol/l)	(12)	(12)

0 min restraint stress	33.8 ± 4.7	35.9 ± 5.3

30 min restraint stress	622.9 ± 87.4	661.0 ± 98.1

1 h post restraint stress	155.7 ± 27.8	181.9 ± 26.8


Level of lesion	Number of patients	Percentage

Thoracic	3	3.49

Thoracolumbar	6	6.98

Lumbar	23	26.74

Lumbosacral	18	20.93

Sacral	16	18.60

Sacrococcygeal	1	1.16

Not available	19	22.09

Total	86	100


	β	t	p

Maternal age (per year)	−0.008	−0.45	0.65

Maternal weight (per kg)	0.211	11.77	<0.001

Frozen thawed embryo (versus fresh embryo)	0.079	4.25	<0.001

ICSI (versus IVF)	0.009	0.48	0.63

SAGE (versus Vitrolife)	−0.004	−0.24	0.81

Gestational age	0.490	27.38	<0.001

Gender (male versus female)	0.110	6.33	<0.001


	Secretory uric acid transporter

Compound	OAT1	ABCG2

Lesinurad	3.90 ± 0.94	>100

Secretory uric acid transporter

OAT1	ABCG2

3.90 ± 0.94	>100


Pathway	Description

G protein-coupled receptor (GPCR) signaling	There are more than 800 GPR genes in the genome. These receptors activate adenyl cyclase to produce cAMP from ATP, or in the phosphatidylinositol pathway to produce a cell response, depending on the context. Sixteen of these receptors were deregulated in our tumor series (available upon request).

EGFR signaling	This receptor was markedly downregulated. In addition, SOS1 (present in cytosol) was upregulated in this pathway.

ErbB2 signaling	The ligand NRG1 and its receptors ErbB2 and ErbB3 were upregulated. The ErbB2 interacting protein (ERBB2IP) was also upregulated. However, the ErbB4 signaling pathway was not deregulated.

Integrin cell surface interactions	Integrin αIIb β3 signaling presented four upregulated elements. The amyloid β (A4) precursor protein-binding family B member 1-interacting protein (APBB1IP) and downstream effector Talin-1 (TLN1) were upregulated. This upregulation provoked the activation of integrin αIIb β3 and the subsequent activation of tyrosine-protein kinase SYK (SYK), which was also upregulated, by Src.

Pathway	Description

EGFR signaling	This receptor was markedly downregulated. In addition, SOS1 (present in cytosol) was upregulated in this pathway.

ErbB2 signaling	The ligand NRG1 and its receptors ErbB2 and ErbB3 were upregulated. The ErbB2 interacting protein (ERBB2IP) was also upregulated. However, the ErbB4 signaling pathway was not deregulated.

Integrin cell surface interactions	Integrin αIIb β3 signaling presented four upregulated elements. The amyloid β (A4) precursor protein-binding family B member 1-interacting protein (APBB1IP) and downstream effector Talin-1 (TLN1) were upregulated. This upregulation provoked the activation of integrin αIIb β3 and the subsequent activation of tyrosine-protein kinase SYK (SYK), which was also upregulated, by Src.


Characteristic	Case (n = 82)

Age in years

> 45	21

≤ 45	61

Sex

 Male	33

 Female	49

Tumour size, cm	5.94 ± 2.65

Location

 Left	31

 Right	51

Symptoms

 Asymptomatic	48

 Symptomatic	34

Fuhrman grade

 1 to 2	32

 3 to 4	50

TNM stage

 I to II	49

 III to IV	33

pT status

 T1 to T2	64

 T3 to T4	18

pN status

 N0	59

 N1	23

pM status

 M0	78

 M1	4

Surgical treatment

 Radical	55

 Partial	27

Tumour thrombus

 Negative	72

 Positive	10

Characteristic	Case (n = 82)

Tumour thrombus

Negative	72

Positive	10


Annual Report Year	Case Number	Clinical Summary

Patients Treated with FabAV

2001	55	A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with features of anaphylaxis to venom. Within minutes, she was hypotensive, profoundly hypoxic, developed pulmonary edema, and had a seizure. Treatment included intubation with ventilator support, dopamine, and FabAV (dose not reported). She never developed local tissue effects or coagulopathy. Despite maximal therapy, she died five days after envenomation.

2002	69	A 43-year-old man presented with severe hypotension after a rattlesnake bite. He remained hypotensive despite fluids, dopamine, epinephrine, diphenhydramine, steroids, and 26 vials of whole-IgG antivenom. Disseminated intravascular coagulopathy developed. He then received six vials of FabAV, after which his blood pressure improved such that vasopressors were discontinued. He developed epistaxis and oral mucosal bleeding that was treated with 7 additional vials of whole-IgG antivenom and transfusions of platelets, fresh frozen plasma, and cryoprecipitate (response not reported). He developed renal failure, and ultimately died of multi-system organ failure.

2003	424	A 33-year-old man received FabAV for an apparently uncomplicated rattlesnake envenomation. He was discharged from the hospital 24 hours later with only minimal symptoms, and was given a prescription for oxycodone with acetaminophen. He died of an apparent overdose of oxycodone that night.

2004	52	A 52-year-old man presented with a forearm compartment syndrome due to a copperhead snakebite. He received FabAV and underwent a dermotomy of his finger and a fasciotomy of his arm. Subsequently, he developed severe alcohol withdrawal, which was treated with diazepam, haloperidol, and fentanyl, which led to respiratory arrest, aspiration, and acute respiratory distress syndrome. Medical care was withdrawn, and the patient died.

2004	53	A 55-year-old man presented with severe hypotension and coma from apparent intravascular envenomation from a rattlesnake. FabAV therapy and aggressive resuscitation were not initiated for several hours. The patient developed renal failure, disseminated intravascular coagulopathy, and circulatory collapse, and died seven hours after envenomation.

Patients Treated with Unspecified Antivenom

2001	56	A 30-year-old man presented comatose after rattlesnake envenomation. On presentation, he was found to have coagulopathy, thrombocytopenia, and a subarachnoid hemorrhage. He received "10 to 20 vials" of unspecified antivenom, but died after withdrawal of life support.

2005	57	A 32-year-old man presented to the emergency department in respiratory arrest due to anaphylaxis from a rattlesnake bite. He received unspecified antivenom, and subsequently died of anoxic encephalopathy.


Groups	Dose (mg/Kg bw)	Blood antioxidant enzymes

SOD (U/g Hb)	GPX (U/g Hb)	CAT (K/g Hb)

NC	-	2943 ± 104.4 a	51.31±4.2a	1.57 ± 0.6a


	N	Drug	Duration	Subcutaneous adipose tissue	Visceral adipose tissue	Body mass index (kg/m2)	Reference

No change in SAT	30	Rosi versus placebo	24 weeks	MRI: NS	MRI: NS	NS	Sutinen et al. [55]

	108	Rosi versus placebo	48 weeks	DEXA limb fat: NS CT thigh: NS CT s.c. abdomen: NS	CT: NS	NS	Carr et al. [56]

	14	Pio versus feno versus pio + feno versus placebo	12 months	DEXA upper limb fat: NS DEXA lower limb fat: NS CT s.c. abdomen: NS	CT: NS	NS	Gavrila et al. [65]

	96	Rosi versus placebo	24 weeks	DEXA limb fat: NSDEXA arm fat: NS DEXA leg fat: NS	ND	NS	Cavalcanti et al. [62]

Increase in SAT	28	Rosi versusplacebo	3 months	CT thigh (cm2): rosi: + 2.3 versus pla −0.9, Δ rosi versus pla, P = .002CT s.c. abdomen: NS DEXA leg: NS (rosi +50 g versus pla −80 g,Δ rosi versus pla P = .08)	CT: NS	NS	Hadigan et al. [57]

	105	Rosi versus metformin versus rosi + met versus placebo	16 weeks	DEXA leg fat (%): rosi: +4.8,*NS; met: −3.6,*NS; rosi + met: −0.5,*NS; pla: −8.3%,*NS Δ rosi vs pla P = .03, other groups versus pla, NSDEXA arm fat: NS DEXA limb fat: NS CT s.c. abdomen: NS	CT (%): rosi: 0.0,*NS; met: −0.6,*NS; rosi + met:−7.9,*NS; pla: −7.2,*NS Δ rosi versus pla, P = .08, other groups versus pla, NS	Body mass index ND, body weight (kg): rosi: 0.0,*NS; met: −2.0,*P < .001; rosi + met: −1.5,*P < .01; pla:−0.05,*NS Δ met versuspla, P = .03; Δ met + rosi versuspla, P = .06	Mulligan et al. [60]

	130	Pio versus placebo	48 weeks	DEXA limb fat (g): pio: +380 g; pla: +50 gΔ pio versus pla P = .051 CT s.c. abdomen: NS	CT: NS	Pio: +0.9; pla: +0.3Δ pio versus pla P = .07	Slama et al. [66]

	39	Rosi versus metformin	26 weeks	CT s.c. abdomen (cm2) rosi: +16,*P < .05; met: −11,*P < .05 Δ rosi versus met 27cm2 (95% CI, 7 to 46)	CT (cm2)rosi: −1,*NS; met: −25,*P < .05 Δ rosi versus met 24 cm2 (95% CI, 6 to 51)	Rosi: +0.4,*P < .05; met: −0.4,*P < .05 Δ rosi versusmet 0.7 (95% CI, 0.5 to 1.6)	van Wijk et al. [58]

	N	Drug	Duration	Subcutaneous adipose tissue	Visceral adipose tissue	Body mass index (kg/m2)	Reference

	108	Rosi versus placebo	48 weeks	DEXA limb fat: NS CT thigh: NS CT s.c. abdomen: NS	CT: NS	NS	Carr et al. [56]

	14	Pio versus feno versus pio + feno versus placebo	12 months	DEXA upper limb fat: NS DEXA lower limb fat: NS CT s.c. abdomen: NS	CT: NS	NS	Gavrila et al. [65]

	96	Rosi versus placebo	24 weeks	DEXA limb fat: NSDEXA arm fat: NS DEXA leg fat: NS	ND	NS	Cavalcanti et al. [62]

Increase in SAT	28	Rosi versusplacebo	3 months	CT thigh (cm2): rosi: + 2.3 versus pla −0.9, Δ rosi versus pla, P = .002CT s.c. abdomen: NS DEXA leg: NS (rosi +50 g versus pla −80 g,Δ rosi versus pla P = .08)	CT: NS	NS	Hadigan et al. [57]

	105	Rosi versus metformin versus rosi + met versus placebo	16 weeks	DEXA leg fat (%): rosi: +4.8,*NS; met: −3.6,*NS; rosi + met: −0.5,*NS; pla: −8.3%,*NS Δ rosi vs pla P = .03, other groups versus pla, NSDEXA arm fat: NS DEXA limb fat: NS CT s.c. abdomen: NS	CT (%): rosi: 0.0,*NS; met: −0.6,*NS; rosi + met:−7.9,*NS; pla: −7.2,*NS Δ rosi versus pla, P = .08, other groups versus pla, NS	Body mass index ND, body weight (kg): rosi: 0.0,*NS; met: −2.0,*P < .001; rosi + met: −1.5,*P < .01; pla:−0.05,*NS Δ met versuspla, P = .03; Δ met + rosi versuspla, P = .06	Mulligan et al. [60]

	130	Pio versus placebo	48 weeks	DEXA limb fat (g): pio: +380 g; pla: +50 gΔ pio versus pla P = .051 CT s.c. abdomen: NS	CT: NS	Pio: +0.9; pla: +0.3Δ pio versus pla P = .07	Slama et al. [66]

	39	Rosi versus metformin	26 weeks	CT s.c. abdomen (cm2) rosi: +16,*P < .05; met: −11,*P < .05 Δ rosi versus met 27cm2 (95% CI, 7 to 46)	CT (cm2)rosi: −1,*NS; met: −25,*P < .05 Δ rosi versus met 24 cm2 (95% CI, 6 to 51)	Rosi: +0.4,*P < .05; met: −0.4,*P < .05 Δ rosi versusmet 0.7 (95% CI, 0.5 to 1.6)	van Wijk et al. [58]


	Group A (non-GBA)	Group B (GBA)	P value

Neck lymphadenopathy	26/60 (43%)	7/14 (50%)	NS

Fissured lips	53/60 (88%)	12/14 (86%)	NS

Strawberry tongue	47/61 (77%)	11/14 (79%)	NS

Conjunctivitis	55/60 (92%)	12/14 (86%)	NS

Skin rash	51/58 (88%)	15/15 (100%)	NS

BCG erythema change	25/58 (43%)	6/13 (46%)	NS

Induration of extremities	39/56 (70%)	3/12 (25%)	NS


Heuristic	Channel Constraint (ω)	Radio Constraint	Network Size	Communication Radius

CR	17%, 25%)	 100%)	)	, 92%)


Essential oil	S. pyogenes

MIC

Cinnamon bark	0.41

Thyme	0.43

Clove	0.10

Peppermint	0.35

Citronella	0.17

Eucalyptus	2.82

Scots pine	1.35


Stimulus 1	Stimulus 2	95% CI Lower bound	Difference of Means (1–2)	95% CI Upper bound	P

TOTALLY ENGAGED (N = 27)

Audio only	Multimodal	–39.72	–28.33	–16.95	<0.001

Music: FAV	Audio only	27.69	39.07	50.46	<0.001

Music: FAV	Multimodal	–0.64	10.74	22.12	0.0682

FRUSTRATED (N = 27)

Audio only	Multimodal	–3.81	6.19	16.18	0.3023

Music: FAV	Audio only	–27.47	–17.48	–7.49	<0.001

Music: FAV	Multimodal	–21.29	–11.30	–1.31	0.0232

Stimulus 1	Stimulus 2	95% CI Lower bound	Difference of Means (1–2)	95% CI Upper bound	P

Audio only	Multimodal	–3.81	6.19	16.18	0.3023

Music: FAV	Audio only	–27.47	–17.48	–7.49	<0.001

Music: FAV	Multimodal	–21.29	–11.30	–1.31	0.0232


Activities Related to HAI Prevention	Professional Groups	N	Average Values in Groups	Median	Standard Deviation	95% CI

Hand-hygiene	Medical student	28	5.6	6.0	2.71	4.649, 6.494

Medical intern	18	6.2	7.0	2.71	4.873, 7.571

Physician	54	6.0	7.0	2.78	5.241, 6.759

Use of disposable gloves	Medical student	28	6.6	7.0	1.52	6.016, 7.198

Medical intern	18	5.0	5.5	2.57	3.724, 6.276

Physician	54	4.9	5.0	2.41	4.229, 5.548

Adherence to aseptic technique	Medical student	28	5.2	5.0	1.97	4.451, 5.978

Medical intern	18	5.5	6.0	2.50	4.255, 6.745

Physician	54	5.3	6.0	2.63	4.616, 6.051

Activities Related to HAI Prevention	Professional Groups	N	Average Values in Groups	Median	Standard Deviation

Hand-hygiene	Medical student	28	5.6	6.0	2.71

Medical intern	18	6.2	7.0	2.71

Physician	54	6.0	7.0	2.78

Use of disposable gloves	Medical student	28	6.6	7.0	1.52

Medical intern	18	5.0	5.5	2.57

Physician	54	4.9	5.0	2.41

Adherence to aseptic technique	Medical student	28	5.2	5.0	1.97

Medical intern	18	5.5	6.0	2.50

Physician	54	5.3	6.0	2.63


Mean height velocity range (cm)	4.50 -8.00				4.00 - 8.40


Identified Motif Sequence	# Seqs withMotif	Motif E-Value	TRANS FAC Hit ID	TRANS AC Binding Site Sequence	TRANS FAC annotation

CATCCAACGGC	29	1.2E-1	M00227	TCCAACGGC	Myb

CCCGCCACGCGCCAC	48	5.1E-26	M00187	GCCACG<underline>T</underline>GCC	Helix Loop Helix

TGGCGGGA	50	5.8E-13	M00024	TGGCG<underline>C</underline>GA	Elongation Factor 2

CCAAACCC	50	2.7E-5	No Hit

CCACCACCACC	48	3.8E-16	No Hit

ACACAACACAC	45	2.2E-10	No Hit

AAAATAAAAATAAAA	9	2.27E-7	No Hit

AATAAAAAAATAAAA	8	1.51E-7	No Hit

AGCTAGCTAGC	6	1.47E-7	No Hit

AGCGAGCGAGC	4	6.23E-8	No Hit

AGCAAGCTAGC	3	2.47E-7	No Hit

Identified Motif Sequence	# Seqs withMotif	Motif E-Value	TRANS FAC Hit ID	TRANS AC Binding Site Sequence	TRANS FAC annotation

CATCCAACGGC	29	1.2E-1	M00227	TCCAACGGC	Myb

CCCGCCACGCGCCAC	48	5.1E-26	M00187	GCCACGTGCC	Helix Loop Helix

TGGCGGGA	50	5.8E-13	M00024	TGGCGCGA	Elongation Factor 2

CCAAACCC	50	2.7E-5	No Hit

CCACCACCACC	48	3.8E-16	No Hit

ACACAACACAC	45	2.2E-10	No Hit

AAAATAAAAATAAAA	9	2.27E-7	No Hit

AATAAAAAAATAAAA	8	1.51E-7	No Hit

AGCTAGCTAGC	6	1.47E-7	No Hit


	Number	Percentage (%)

1 year follow up	66	81.5

Lost to follow up	5	6

Deceased at 1 year	10	12.3

Referral done to specialized cardiology center	37	45.6

Underwent Exercise ECG	22	27

Underwent Coronary angiogram	10	12.3

Underwent Revascularization	7	7.3

Re-admitted with Coronary events	6	7.4

	Number	Percentage (%)

Deceased at 1 year	10	12.3

Referral done to specialized cardiology center	37	45.6

Underwent Exercise ECG	22	27

Underwent Coronary angiogram	10	12.3

Underwent Revascularization	7	7.3

Re-admitted with Coronary events	6	7.4


Modification	Hypotheses tested

Ranking task	Introducing the ranking task prior to the cTTO valuation will reduce the inconsistencies and improves the overall data quality (i.e. more WTD responses).

BTD/WTD split	Separating the BTD and WTD cTTO tasks will reduce the inconsistencies of the valuations and improve the overall data quality (i.e. more WTD responses, higher values for mild heath state and fewer spikes).

Feedback module	Presenting respondents with the rank ordering implied by their cTTO valuations will reduce the inconsistencies as they will identify and flag problematic valuations for removal from the data.


Viroid small RNAs (vd-sRNAs)	Reference

vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis	Di Serio et al., 2009; Navarro et al., 2012a

Gaining further insights into the genesis and role of vd-RNAs of hop stunt viroid and grapevine yellow speckle viroid 1 in plant–viroid interaction	Navarro et al., 2009

vd-sRNAs from PSTVd-infected wild-type and RDR6i Nicotiana benthamiana plants accumulate to levels paralleling their genomic RNA, display similar patterns with prevailing 22- or 21-nt plus-strand species, and adopt strand-specific hot spot profiles	Di Serio et al., 2010

The pathway involved in the biogenesis of vd-sRNAs of hop stunt viroid was studied and revealed	Martinez et al., 2010

Characterization of vd-sRNA of hop stunt viroid, grapevine yellow speckle 1 and grapevine yellow speckle 2 viroids in grapevine	Alabi et al., 2012

vd-sRNAs of peach latent mosaic viroid (PLMVd) were characterized. Similarly to host microRNAs (miRNAs), two PLMVd vd-sRNA derived from the pathogenic determinant of an extreme albinism direct cleavage of a specific host mRNA, strongly suggesting their involvement in symptom expression	Navarro et al., 2012a

Based on the observation that viroid-infected plants generate vd-sRNAs 21–24 nt, an approach was developed to utilize several bioinformatic tools for identifying novel and known viroids and viroid-like circular RNAs in sRNA libraries	Wu et al. (2012)

vd-sRNAs derived from potato spindle tuber viroid variants inducing different symptoms, may aim at multiple and different host mRNA targets	Wang et al., 2011; Piernikarczyk et al., 2013

Computational algorithms as bioinformatic tools were utilized to identify circular RNAs of viroid or satellite sRNAs	Zhang et al., 2014

Extending the host range of apple dimple fruit viroid to fig	Chiumenti et al., 2014

Inoculation with a single variant of peach latent mosaic viroid generates a highly heterogeneous progeny within a single infected peach seedling. The most distant variants displayed a 17% variation level when compared to the parent sequence	Glouzon et al., 2014

vd-sRNAs of potato spindle tuber viroid (PSTVd) and effects of artificial miRNA derived from PSTVd-mild or -severe infected plants were analyzed. Differences in the distribution of vdsRNAs hot spots were observed. Data suggest involvement of vd-sRNAs in symptom expression	Adkar-Purushothama et al., 2015; Avina-Padilla et al., 2015

Extending the host range of hop stunt viroid to chickpea	Pirovano et al., 2015

Viroid small RNAs (vd-sRNAs)	Reference

vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis	Di Serio et al., 2009; Navarro et al., 2012a

Gaining further insights into the genesis and role of vd-RNAs of hop stunt viroid and grapevine yellow speckle viroid 1 in plant–viroid interaction	Navarro et al., 2009

vd-sRNAs from PSTVd-infected wild-type and RDR6i Nicotiana benthamiana plants accumulate to levels paralleling their genomic RNA, display similar patterns with prevailing 22- or 21-nt plus-strand species, and adopt strand-specific hot spot profiles	Di Serio et al., 2010

The pathway involved in the biogenesis of vd-sRNAs of hop stunt viroid was studied and revealed	Martinez et al., 2010

Characterization of vd-sRNA of hop stunt viroid, grapevine yellow speckle 1 and grapevine yellow speckle 2 viroids in grapevine	Alabi et al., 2012

vd-sRNAs of peach latent mosaic viroid (PLMVd) were characterized. Similarly to host microRNAs (miRNAs), two PLMVd vd-sRNA derived from the pathogenic determinant of an extreme albinism direct cleavage of a specific host mRNA, strongly suggesting their involvement in symptom expression	Navarro et al., 2012a

Based on the observation that viroid-infected plants generate vd-sRNAs 21–24 nt, an approach was developed to utilize several bioinformatic tools for identifying novel and known viroids and viroid-like circular RNAs in sRNA libraries	Wu et al. (2012)

vd-sRNAs derived from potato spindle tuber viroid variants inducing different symptoms, may aim at multiple and different host mRNA targets	Wang et al., 2011; Piernikarczyk et al., 2013

Computational algorithms as bioinformatic tools wer	Zhang

Viroid small RNAs (vd-sRNAs)	Reference

e utilized to identify circular RNAs of viroid or satellite sRNAs	et al., 2014

Extending the host range of apple dimple fruit viroid to fig	Chiumenti et al., 2014

Inoculation with a single variant of peach latent mosaic viroid generates a highly heterogeneous progeny within a single infected peach seedling. The most distant variants displayed a 17% variation level when compared to the parent sequence	Glouzon et al., 2014

vd-sRNAs of potato spindle tuber viroid (PSTVd) and effects of artificial miRNA derived from PSTVd-mild or -severe infected plants were analyzed. Differences in the distribution of vdsRNAs hot spots were observed. Data suggest involvement of vd-sRNAs in symptom expression	Adkar-Purushothama et al., 2015; Avina-Padilla et al., 2015

Extending the host range of hop stunt viroid to chickpea	Pirovano et al., 2015


Parameter	Value

	n = 4068

Age (n,%)

 18-34	20	0.5

 35-44	108	2.7

 45-54	513	12.6

 55-64	1,481	36.4

 > = 65	1,946	47.8

Geographic region (n,%)

 Northeast	538	13.2

 Northcentral	1,249	30.7

 South	2,071	50.9

 West	208	5.1

Payer type (n,%)

 HMO	81	2.0

 Indemnity	1,814	44.6

 PPO	1,210	29.7

 POS	941	23.1

 Other	21	0.5

Comorbidities (n,%)

 Cerebrovascular Disease	426	10.5

 Coronay heart disease	910	22.4

 Heart failure	66	1.6

 Peripheral arterial disease	165	4.1

 Diabetes	808	19.9

 Kidney Disease	60	1.5

 Liver Disease	272	6.7

 Respiratory Disease	2,384	58.6

Health care expenditures prior to index date (mean, SD)

 -365 days	28,562	31,136

Parameter

Age (n,%)

18-34

35-44

45-54

55-64

> = 65

Geographic region (n,%)

Northeast

Northcentral

South

West

Payer type (n,%)

HMO

Indemnity

PPO

POS

Other

Comorbidities (n,%)

Cerebrovascular Disease

Coronay heart disease

Heart failure

Peripheral arterial disease

Diabetes

Kidney Disease

Liver Disease

Respiratory Disease

Health care expenditures prior to index date (mean, SD)

-365 days


Combination	Nr of MRSA strains (%) for which combinations gave


Gene	Number of exons	Number of mutations worldwide**	Number of homopolymer repeats* in CDS	Function in hearing process

GJB2	2	> 220	0	ion homeostasis

SLC26A4	21	43	7	ion homeostasis

MYO15A	66	28	8	hair bundle, motor protein

OTOF	48	26	4	exocytose at auditory ribbon synapse

CDH23	69	21	4	hair bundle, adhesion protein

TMC1	24	20	4	unknown function

TMPRSS3	13	16	3	unknown function

TECTA	23	10	2	extracellular matrix protein

TRIOBP	24	9	7	hair bundle, cytoskeletal formation

TMIE	4	8	0	unknown function

PJVK	7	7	3	signaling of hair cells and neurons

ESPN	13	6	1	hair bundle, cytoskeletal formation

PCDH15	33	5	8	hair bundle, adhesion protein

ESRRB	12	5	1	transcription factor

MYO7A	49	5	5	hair bundle, motor proteins

Gene	Number of exons	Number of mutations worldwide**

GJB2	2	> 220

SLC26A4	21	43

MYO15A	66	28

OTOF	48	26

CDH23	69	21

TMC1	24	20

TMPRSS3	13	16

TECTA	23	10

TRIOBP	24	9

TMIE	4	8

PJVK	7	7

ESPN	13	6

PCDH15	33	5

ESRRB	12	5

MYO7A	49	5

Number of homopolymer repeats* in CDS	Function in hearing process

0	ion homeostasis

7	ion homeostasis

8	hair bundle, motor protein

4	exocytose at auditory ribbon synapse

4	hair bundle, adhesion protein

4	unknown function

3	unknown function

2	extracellular matrix protein

7	hair bundle, cytoskeletal formation

0	unknown function

3	signaling of hair cells and neurons

1	hair bundle, cytoskeletal formation

8	hair bundle, adhesion protein

1	transcription factor

5	hair bundle, motor proteins


Parameter	Temperature (K)

293 	303 	313

−ΔG° (kJ mol−1)	6.543	6.063	5.687

−ΔH° (kJ mol−1)	16.869

−ΔS° (kJ mol−1 K−1)	0.0353

Ea (kJ mol−1)	3.309


Participant code	Sex	Age (yrs)	BMI (kg/m2)	Injury level and AIS score	Years since SCI	Medications	Treatment

1	M	46	32.9	C5A	23.3	Baclofen, Temazepam	CPAP

2	M	68	27.7	C4A	23.9	Baclofen 	CPAP

3	F	28	20.3	C5A	4.10	Baclofen, Diazepam	—

4	M	42	20.8	C6A	17.10	Baclofen, Diazepam	Oral Splint

5	M	26	18.5	C6A	10.10	Baclofen 	—

Positive control

1	M	43	24.8	—	—	—	—

2	F	31	20.7	—	—	—	—


 	 	Women	Men

 	 	N = 214	N = 154

 	 	OR	p	OR	p

Surgical specialties	Combining work with family	0.4 (0.3–0.6)	.000	0.4 (0.3–0.7)	.000

 	Good salarya	1.9 (1.2–3.0)	.004	0.8 (0.5–1.3)	NS

 	In line with technical skills	1.4 (1.0–1.9)	.034	1.9 (1.2–3.0)	.011

 	Lots of direct patient contact	0.9 (0.6–1.3)	NS	0.6 (0.4–0.9)	.018

Non-surgical specialties	Research opportunities	1.4 (1.0–1.9)	.023	1.9 (1.3–2.9)	.001

 	Good salary	0.4 (0.2–0.6)	.000	0.8 (0.5–1.3)	NS

 	Interesting content	2.4 (1.0–5.5)	.048	1.7 (0.8–3.9)	NS

Family medicine	Lots of direct patient contact	3.7 (1.8–7.9)	.001	2.9 (1.4–6.0)	.005

 	Career prospectsa	0.4 (0.2–0.7)	.002	0.8 (0.4–1.5)	NS

 	Combining work with family	2.3 (1.3–4.2)	.004	1.6 (0.9 –2.9)	NS

 	Good salary	1.9 (1.1–3.3)	.018	1.7 (0.9–3.2)	NS

 	Interesting content	0.4 (0.2–0.9)	.024	0.8 (0.4–1.9)	NS

 	In line with technical skills	0.6 (0.4–1.0)	.045	0.7 (0.5–1.2)	NS

 	Research opportunities	0.8 (0.6–1.3)	NS	0.6 (0.4–1.0)	.031

Uncertain	Combining work with family	2.1 (1.5–3.1)	.000	1.8 (1.2–2.7)	.005

 	Lots of direct patient contact	0.6 (0.4–0.8)	.003	1.0 (0.7–1.5)	NS


Authors	Intervention	Patient Population	Design	No. of Patients	Outcome

Pizzocarro et al15	IFN-α2b v placebo	Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0)	Multicenter, randomized, controlled trial	247	5-year OS: 0.665 (control) v 0.660 (treatment) (HR 1.040; 95% CI, 0.671 - 1.613, P = 0.861)

5-year DFS: 0.671 (control) v 0.567 (treatment) (HR 1.412; 95% CI, 0.927–2.149, P = .107)

Messing et al16	IFN-α-NL v observation	pT3–4a and/or node-positive)	Multicenter, randomized, controlled trial	283	At 10.4 years median follow-up:

Median survival: 7.4 years (control) v 5.1 years (treatment) (P = .09).

DFS: 3.0 years (control) v 2.2years (treatment) (P = .33)

Clark et al17	IL-2 v observation	T3b-4 or N1–3 (LA) or M1	Multicenter, randomized, controlled trial	69 total; 44 LA, 25 M1 disease	2-year DFS: 48% (control in LA patients) v 53% (treatment in LA patients) (P = 0.73)

2-year OS: 77% (control in LA patients) v 86% (treatment in LA patients) (P = .38)

Passalacqua et al18	IL-2 and IFN-α v observation	pT1, T2, T3 a-b-c; pN0-pN3, M0	Multicenter, randomized, controlled trial	310	5-year DFS: 0.73 (control) v 0.73 (treatment)

10-year DFS: 0.60 (control) v 0.73 (treatment) (HR 0.84; 95% CI, 0.54–1.33, P = 0.47)

Atzpodien et al19	IL-2 and IFN-α2a and intravenous 5 v fluorouracil	pT3b/c pN0 or pT4pN0), pN, complete resection of tumor relapse or solitary metastasis (R0)	Multicenter, randomized, controlled trial	203	At median follow-up of 4.3 years:

2-year OS: 91% (control) v 81% (treatment)

5-year OS: 76% (control) v 58% (treatment)

8-year OS: 66% (control) v 58% (treatment) (P = 0.0278)

2-year DFS: 62% (control) v 54% (treatment)

5-year DFS: 49% (control) v 42% (treatment)

8-year DFS: 49% (control) v 39% (treatment) (P = 0.2398)

Aitchison et al22	IL-2 and IFN-α2a and intravenous 5-fluorouracil	T3b-c,T4 or any pT and pN 1 or pN 2 or positive microscopic margins or microscopic vascular invasion	Multicenter, randomized, controlled trial	309	3-year DFS: 50% (control) v 60% (treatment) (HR 0.87; 95% CI, 0.63-1.20)

5 year OS: 60% (control) v 68% (treatment) (HR 0.91; 95% CI, 0.60–1.38)

Galligioni et al24	Autologous irradiated tumor cells & BCG v observation	Stages I, II, and III	Prospective, randomized, controlled trial	120	At 61 months median follow-up:

5-year OS: 78% (control) v 69% (treatment)

5-year DFS: 72% (control) v 63% (treatment)

Adler et al25	Autologous irradiated tumor cells & BCG & hormone v hormone	All stages	Prospective, randomized, controlled trial	43	Trend for prolongation of DFS for stage I, II, and III

(P<.1)

Wood et al26	Autologous, tumor-derived heat-shock protein (glycoprotein 96)–peptide complex (HSPPC-96; vitespen) v observation	cT1b–T4 N0 M0, or cT any N1-2 M0	Multicenter, randomized, controlled trial	819	At 1.9 years median follow-up:

Recurrence: 39.8% (control) v 37.7% (treatment) (HR 0·923; 95% CI, 0·729–1·169, P = .506)

OS not mature

Jocham et al27	Autologous renal tumor cells (Reniale)	pT2–3b pN0–3 M0	Multicenter, randomized, controlled trial	558	At 5-year follow-up:

DFS: 67.8% (control) v77.4% (treatment) (P = .0204) At 70-month follow-up:

DFS: 59.3% (control) v 72% (treatment)

HR for tumor progression: 1.58 (95% CI 1.05–2.37) and 1.59 (1.07–2.36) (P = .0204)

Authors	Intervention	Patient Population	Design	No. of Patients	Outcome

Pizzocarro et al15	IFN-α2b v placebo	Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0)	Multicenter, randomized, controlled trial	247	5-year OS: 0.665 (control) v 0.660 (treatment) (HR 1.040; 95% CI, 0.671 - 1.613, P = 0.861)

5-year DFS: 0.671 (control) v 0.567 (treatment) (HR 1.412; 95% CI, 0.927–2.149, P = .107)

Messing et al16	IFN-α-NL v observation	pT3–4a and/or node-positive)	Multicenter, randomized, controlled trial	283	At 10.4 years median follow-up:

Median survival: 7.4 years (control) v 5.1 years (treatment) (P = .09).

DFS: 3.0 years (control) v 2.2years (treatment) (P = .33)

Clark et al17	IL-2 v observation	T3b-4 or N1–3 (LA) or M1	Multicenter, randomized, controlled trial	69 total; 44 LA, 25 M1 disease	2-year DFS: 48% (control in LA patients) v 53% (treatment in LA patients) (P = 0.73)

2-year OS: 77% (control in LA patients) v 86% (treatment in LA patients) (P = .38)

Passalacqua et al	IL-2 and	pT1, T2	Multicenter, 	31	5-year DFS: 0.73 (contro

18	 IFN-α v observation	, T3 a-b-c; pN0-pN3, M0	randomized, controlled trial	0	l) v 0.73 (treatment)

10-year DFS: 0.60 (control) v 0.73 (treatment) (HR 0.84; 95% CI, 0.54–1.33, P = 0.47)

Atzpodien et al19	IL-2 and IFN-α2a and intravenous 5 v fluorouracil	pT3b/c pN0 or pT4pN0), pN, complete resection of tumor relapse or solitary metastasis (R0)	Multicenter, randomized, controlled trial	203	At median follow-up of 4.3 years:

2-year OS: 91% (control) v 81% (treatment)

5-year OS: 76% (control) v 58% (treatment)

8-year OS: 66% (control) v 58% (treatment) (P = 0.0278)

2-year DFS: 62% (control) v 54% (treatment)

5-year DFS: 49% (control) v 42% (treatment)

8-year DFS: 49% (control) v 39% (treatment) (P = 0.2398)

Aitchison et al22	IL-2 and IFN-α2a and intravenous 5-fluorouracil	T3b-c,T4 or any pT and pN 1 or pN 2 or positive microscopic margins or microscopic vascular invasion	Multicenter, randomized, controlled trial	309	3-year DFS: 50% (control) v 60% (treatment) (HR 0.87; 95% CI, 0.63-1.20)

5 year OS: 60% (control) v 68% (treatment) (HR 0.91; 95% CI, 0.60–1.38)

Galligioni et al24	Autologous irradiated tumor cells & BCG v observation	Stages I, II, and III	Prospective, randomized, controlled trial	120	At 61 months median follow-up:

5-year OS: 78% (control) v 69% (treatment)

5-year DFS: 72% (control) v 63% (treatment)

Adler et al25	Autologous irradiated tumor cells & BCG & hormone v hormone	All stages	Prospective, randomized, controlled trial	43	Trend for prolongation of DFS for stage I, II, and III

(P<.1)

Wood et al26	Autologous, tumor-derived heat-shock protein (glycoprotein 96)–peptide complex (HSPPC-96; vitespen) v observation	cT1b–T4 N0 M0, or cT any N1-2 M0	Multicenter, randomized, controlled trial	819	At 1.9 years median follow-up:

Recurrence: 39.8% (control) v 37.7% (treatment) (HR 0·923; 95% CI, 0·729–1·169, P = .506)

OS not mature

Jocham et al27	Autologous renal tumor cells (Reniale)	pT2–3b pN0–3 M0	Multicenter, randomized, controlled trial	558	At 5-year follow-up:

DFS: 67.8% (control) v77.4% (treatment) (P = .0204) At 70-month follow-up:

DFS: 59.3% (control) v 72% (treatment)

HR for tumor progression: 1.58 (95% CI 1.05–2.37) and 1.59 (1.07–2.36) (P = .0204)


Primary	Definition

Tumor (T)

Tx	Primary tumor cannot be assessed

T0	No evidence of primary tumor

Tis	Carcinoma in situ

T1	Tumor 2 cm or less in greatest dimension and no medullary bone invasion

T2	Tumor more than 2 cm but not more than 4 cm in greatest dimension and no bone invasion or tumor 2 cm or less in greatest dimension with medullary bone invasion

T3	Tumor more than 4 cm in greatest dimension and no medullary bone invasion or tumor more than 2 cm but not more than 4 cm with medullary bone invasion

T4a	Tumor more than 4 cm in greatest dimension with medullary bone invasion or tumor invades into mandibular canal, deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face

T4b	Tumor invades masticator space, pterygoid plates, or skull base; or encases internal carotid artery

Primary

Tumor (T)

Tx

T0

Tis

T1

T2

T3

T4a

T4b

Definition

Primary tumor cannot be assessed

No evidence of primary tumor

Carcinoma in situ

Tumor 2 cm or less in greatest dimension and no medullary bone invasion

Tumor more than 2 cm but not more than 4 cm in greatest dimension and no bone invasion or tumor 2 cm or less in greatest dimension with medullary bone invasion

Tumor more than 4 cm in greatest dimension and no medullary bone invasion or tumor more than 2 cm but not more than 4 cm with medullary bone invasion

Tumor more than 4 cm in greatest dimension with medullary bone invasion or tumor invades into mandibular canal, deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face

Tumor invades masticator space, pterygoid plates, or skull base; or encases internal carotid artery


Location of study village	Types of prevention practices reported	Frequency & motivation for bed net use	Influences on preventative health behaviours	Community suggestions for participation in malaria elimination

North Tanna	Use of bed netsClean home/personalhygieneProtective clothingTidy village/sourceInsect spray	Some reported seasonal use others reported year round use (varies at household & individual levels)Motivation to nets for both mosquito nuisance and protection from malariaNet rarely used whentravelling	Health officers most influential (VHW, nurse)Church leaders, chiefs &Village eldersTeachersMothers most influentialon health behaviours ofchildrenRisk perceptionAcceptability andPractical issues	Take advice of village leadersSet example for othersTidy village/sourcereducton activitiesUse bed netsMosquito sprayand coilsUse fire/smoke for protection outsideImprove roads to Lenakel/closer clinics for treatment

Middle Bush	Use of bed netsClean homeTidy village/sourcereductionDrinking clean waterBlanket for protectionwhen sleeping duringtravel	Mostly seasonal use of bed netsPrimary motivation ismosquito nuiscanceNet rarely used whentravelling	Doctors & health officersCheif & church leadersTeachersHousehold heads influencefamily practicesMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues	Village leaders to spread messagesLeaders to set example for othersTidy village/sourcereduction activitiesUse bed netsImprove access to earlyand effectivetreatment

South Tanna	Use of bed netsClean home/personalhygieneTidy village/sourcereductionFire/smoke as repellentBlanket for protectionwhen travelling	Some reported seasonal use others year round use (varies at household &individual levels)Motivation to use nets forboth mosquito nuiscanceand protection frommalariaNet rarely used whentravelling	Health officers Church leaders, chief and village eldersHousehold heads influencefamilyMothers influence healthpractices of childrenRisk perceptionAcceptability andpractical issues	Village leaders to encourage participationTidy village/sourcereduction activitiesUse bed netsSupport IRS

Homogeneity/ Heterogeneity of responses	Homogeneity in types of protection methods used across the 3 villages	Heterogeneity between the Middle Bush village and other 2 villages due to absence of malaria	Homogeneity in influences on health behaviours across the 3 villages	Homogeneity in ideas for participation in malaria prevention across the 3 villages


Exon	Primers (3′-5′)	Annealing temperature (°C)	Buffer pH	MgCl2 (mM)	% DMSO	Fragment (bp)

1	F: GCAGATTTAAAGCAACACCACC	60	8.4	1	0	242

R: CCCCTTCAAATTATCCTCAGC

2	F: CTAGTGATTCATCGATGTAGCTC	52	8.4	1	10	370

R: TTTCCAGCTCCTCTGGTCATTGC

3	F: TGATGTCAGTTTTCAAAGTTTTCC	54	8.4	1	0	313

R: TAATTAGCAAAACTGAGAGAGTGG

4	F: GCACACATTAAATTTGTTTCTGCA	54	8.4	1.5	0	345

R: TACCACTTTGTCAGATTATAGATG

5	F: TAGTAACTCCACATTTTTCTATAC	50	8.4	1.5	0	301

R: TAAGTGCAAAGTAATAGTAACTGT

6	F: AATATTTTCAGAGTAAGCACTCAT	50	8.4	1.5	0	288

R: ACACTTTATACAATCCCAATCAAA

7	F: GTGATGTTGCTTAAAAGCATCAAAC	54	8.6	1.5	0	325

R: CTTGTAAAGAAGCAACAAGATCAAC

8	F: CCATTTTCCTGAAACACTACCCTA	52	8.4	1.5	0	377

R: TTGGGGTACAGTGCAACAGATTAG

9	F: AATTATTTGAATTTCCAGACACCT	50	8.4	1.5	0	375

R: GGGTTATTCTATGAAATTAGTCCA

10	F: GCAATTTCACTATTCTATGAAAGG	52	8.4	1.5	0	348

R: ACAGAATTGGCTACATAATGGCT


Factors	β	S.E.	aOR (95% CI)

Residence (rural vs. urban)	0.79	0.36	2.03 (1.30–4.25)

Parental history of T1DM (positive history vs. negative)	3.90	2.54	9.03 (1.02–85.32)

Mod Of Delivery (cesarean vs. vaginal)	0.75	0.43	2.13 (1.09–5.03)

Breast feeding (>6 months vs. <6 months)	−1.46	0.39	0.23 (0.11–0.50)

Introduction of cows milk in first year of life (positive vs. negative)	2.99	0.42	19.94 (8.73–45.53)

Vitamin D Supplementation in first year of life (positive vs. negative)	−2.16	0.37	0.11 (0.05–0.24)

Physical Activity (high vs. low)	−2.90	0.44	0.05 (0.02–0.12)


Substance	Reported Usage	Percent of Survey Participants

Opioid Pharmaceuticals	18	5.95%

Hallucinogens	11	3.63%

MDMA/Ecstasy	10	3.30%

Cocaine/Crack Cocaine	7	2.31%

Benzodiazepine Pharmaceuticals	6	1.98%

Other Substances	5	1.65%

Stimulant Pharmaceuticals	3	0.99%

Methamphetamine	2	0.66%

Heroin	0	0.00%


Variables	Lean	Overweight	Obese	p for heterogeneity

BMI (kg/m2)(mean)	18.5–24.9922.7 ± 1.7	25–29.9927.1 ± 1.6	≥3033.5 ± 3.8

No. of subjects (%)	246 (51)	150 (31)	77 (18)

Sociodemographic variables

 Age (years)	48 ± 16	57 ± 17	61 ± 16	<0.0001

 Female/male	122/124	66/84	49/28	<0.0001

 University degree or higher	180	89	33	<0.0001

 Household income (above median)	149	84	38	0.1

Health behaviors

 Current smoking (%)	16	11	6	0.9

 Physical activity (kJ/d/Kg)	47 ± 20	47 ± 22	43 ± 23	0.44

Health measures

 Systolic blood pressure (BP) (mm Hg)	116 ± 15	123 ± 16	126 ± 19	<0.0001

 Diastolic BP (mm Hg)	71 ± 10	75 ± 11	77 ± 11	<0.0001

Disease diagnosis

 Myocardial infarction	1	3	1	0.3

 Cancer	11	6	9	0.03

 Diabetes	3	6	9	<0.0001

 Stroke	4	0	1	0.3

 High cholesterol	21	17	17	<0.01

 High BP	19	30	29	<0.001

Variables	Lean	Overweight	Obese	p for heterogeneity

Myocardial infarction	1	3	1	0.3

Cancer	11	6	9	0.03

Diabetes	3	6	9	<0.0001

Stroke	4	0	1	0.3

High cholesterol	21	17	17	<0.01

High BP	19	30	29	<0.001


Time since quitting	Beneficial health changes that take place

24 h	Lungs start to clear out mucus and other smoking debris

48 h	Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved

72 h	Breathing becomes easier. Bronchial tubes begin to relax and energy levels increase

2–12 weeks	Circulation improves

3–9 months	Coughs, wheezing and breathing problems improve as lung function is increased by up to 10%

1 year	Risk of a heart attack falls to about half that of a smoker

10 years	Risk of lung cancer falls to half that of a smoker

15 years	Risk of heart attack falls to the same as someone who has never smoked

Time since quitting

24 h

48 h

72 h

2–12 weeks

3–9 months

1 year

10 years

15 years

Beneficial health changes that take place

Lungs start to clear out mucus and other smoking debris

Carbon monoxide will be eliminated from the body. Ability to taste and smell is greatly improved

Breathing becomes easier. Bronchial tubes begin to relax and energy levels increase

Circulation improves

Coughs, wheezing and breathing problems improve as lung function is increased by up to 10%

Risk of a heart attack falls to about half that of a smoker

Risk of lung cancer falls to half that of a smoker

Risk of heart attack falls to the same as someone who has never smoked


Characteristic	N	%

Pre-pregnancy nutritional status (BMI)

Underweight (<18.5 kg/m2)	84	10.9

Normal weight (18.5 – 24.99 kg/m2)	494	63.8

Overweight (25.0 – 29.99 kg/m2)	131	16.9

Obese (≥30.0 kg/m2)	65	8.4

Total weight gain

Low	209	26.9

Intermediate	298	38.4

High	270	34.7

Mode of delivery

Normal	288	49.6

Forceps	22	3.8

Cesarean section	270	46.6

Gestational age at birth

Preterm (<37 weeks)	26	4.7

Term (≥37 weeks)	527	95.3

Weight at birth

Low (<2500 g)	33	4.3

Normal (2500 g - 3999 g)	695	91.1

High (≥4000 g)	35	4.6

Pregnancy complications

None	455	54.9

Other	347	41.9

Gestational diabetes mellitus	27	3.3

Characteristic	N	%

Pre-pregnancy nutritional status (BMI)

Underweight (<18.5 kg/m2)	84	10.9

Normal weight (18.5 – 24.99 kg/m2)	494	63.8

Overweight (25.0 – 29.99 kg/m2)	131	16.9

Obese (≥30.0 kg/m2)	65	8.4

Total weight gain

Low	209	26.9

Intermediate	298	38.4

High	270	34.7

Mode of delivery

N	2	49

ormal	88	.6

Forceps	22	3.8

Cesarean section	270	46.6

Gestational age at birth

Preterm (<37 weeks)	26	4.7

Term (≥37 weeks)	527	95.3

Weight at birth

Low (<2500 g)	33	4.3

Normal (2500 g - 3999 g)	695	91.1

High (≥4000 g)	35	4.6

Pregnancy complications

None	455	54.9

Other	347	41.9

Gestational diabetes mellitus	27	3.3


Analysis	Number of plants assayed	Number of tolerant plants	Transformation frequency

Basta leaf paint	78	70	89.73%

Kanamycin/paromomycin Leaf bleach	34	32	94.12%


Plant specie	 Aa length	PTS1	pI	Molecular Mass (kDa)	Accession number

Arabidopsis thaliana	486	-SKI	7.02 	53.6	AEE73797.1

Cleome spinosa	485	-SMI	5.80	53.6	ABD96861.1

Medicago sativa	486	-SRI	5.33	53.7	AAB41553.1

Oryza sativa	480	-AKM	5.85	52.7	AJB98434.1

Pinus sylvestris	483	-SKI	6.31	53.3	ADP03057.1

Pinus pinaster	483	-SKI	6.74	53.2	ADP03318.1

Spinacia oleracea	483	-SKI	6.04	53.2	AAK51690.1

Vitis vinifera	438	-SKI	8.13	48.3 	CAN67602.1

Zea mays	480	-SKI	6.09	52.7	ACN35899.1

Plant specie	Aa length	PTS1	pI	Molecular Mass (kDa)	Accession number

Vitis vinifera	438	-SKI	8.13	48.3	CAN67602.1

Zea mays	480	-SKI	6.09	52.7	ACN35899.1


Oil	Isothermal T (°C)	t0 (min)	tmax(min)	Regression equationa	R2b	Reported t0 or shelf life at 20 °C (d)

Linola

	100	170.7	287.1	Log (k) = 0.0211 T-4.3479	0.9987	5.9

	110	108.3	183.7

	120	64.6	114.5


Resource	Brief description	Included information

Facilitator manual	Comprehensive train-the-trainer manual detailing all information required for the delivery of the program	* Introduction* Successful facilitating* Background to the research* Session guides

Manual for Dads	Handbook for fathers that includes a summary of the information from the face-to-face sessions and additional background information	* Session 1: Weight loss fundamentals for men* Session 2: Raising children in an inactive world* Session 3: Ready to rumble with dad* Session 4: Healthy eating for families - dads matter* Session 5: Fun, fitness and fundamental movement skills* Session 6: Sustaining healthy lifestyles* Session 7: Weight loss is a journey not a destination

Dad's log book	Handbook that dads use as a working document	* Program activities: Energy calculations; sedentary behaviors; goal setting; eating habits* Homework activities: Children's screen time; family fitness activity; family cooking; children's food intake; cue words; family activity* Monitoring procedures: Pedometer chart; weight loss chart; goal recording

Website user guide	Handbook to guide fathers through the setup and use of the dietary and physical activity monitoring website	* Setting up a profile* Food and exercise diary* Check in diary* Charts and reports

Kid's Handbook	Includes tasks for children to complete each week with their dads that must be signed off with their dads (space to receive a sticker from facilitators if completed)	* Kids homework activities* Recipes to cook with dad

Green slips	Homework activity slips given to fathers at the end of each session	* Activities are designed to align with the principles presented at the intervention session and any activities detailed in the Dad's log book and Kid's handbook (e.g. cooking meals with kids, family fundamental movement skills circuit, rough and tumble games with dad)


	Kindergarten	Elementary school	Junior high school	P-valueb

	n (%)	n (%)	n (%)

Feeling upon awakening


Instrument	Countries

Supply side regulation: in patent drugs

Price controls: administrative or statutory pricing	All EU Member States except Germany, UK and, to a certain extent, Sweden

External reference pricing	All EU Member States except UK, Germany, Sweden

Rate of return regulation	UK

Negotiations and price-volume agreements	France, Italy, Austria

Direct expenditure controls: payback	France, Portugal, Austria

Direct expenditure controls: price volume agreements	France

Cost-plus pricing	Spain

Supply side regulation: off patent drugs

Tendering for generics pharmaceuticals in primary care	Netherlands, Germany

Price capping for generics and linking these to the originator price	Italy, Greece, France

Supply side regulation: reimbursement methods

Positive and negative formularies	All EU Member States

Internal reference pricing	Germany, Netherlands, Czech Republic, Italy, Spain, France, Hungary

Health Technology Assessments (HTA)	UK, Sweden, Netherlands, Hungary, Poland, Finland, Estonia, Latvia, Lithuania. In France only assessment of clinical benefit

Innovative pricing and reimbursement schemes	Italy, Germany, UK, Finland

Demand side regulation: policies towards physicians

Clinical practice guidelines	All EU Member States

Compulsory generic prescribing	UK, Denmark, Estonia

Financial incentives	France, UK

Prescription monitoring and audit	Belgium, UK, Netherlands, France, Denmark, Sweden, Estonia

Demand side regulation: policies towards pharmacies

Control of remuneration (e.g. margins, fees) including contractual arrangements	All Member States

Generic substitution	France, Italy, Spain, Sweden

Demand side regulation: policies towards patients

Cost-sharing	All EU Member States

Encouraging use of over-the counter medicines and “de-listing”	UK, Germany, Sweden, Netherlands

Instrument	Countries

Prescription monitoring and audit	Belgium, UK, Netherlands, France, Denmark, Sweden, Estonia

Demand side regulation: policies towards pharmacies

Control of remuneration (e.g. margins, fees) including contractual arrangements	All Member States

Generic substitution	France, Italy, Spain, Sweden

Demand side regulation: policies towards patients

Cost-sharing	All EU Member States

Encouraging use of over-the counter medicines and “de-listing”	UK, Germany, Sweden, Netherlands


		Male	Female

		CCU or ICU	Medical ward	CCU or ICU	Medical ward

Age groups	Standard Population	Death rate %	Expected # death	Death rate %	Expected # death	Death rate %	Expected # death	Death rate %	Expected # death

All ages	4859

18–54	1223	0.53	6.5	0.97	11.9	1.10	13.5	2.70	33.0

55–65	1245	1.78	22.2	1.84	22.9	1.72	21.4	1.52	18.9

6	128		3	3.		2	3	3.9	51


ATC Code	Drug classification	No. of visits 	%

G01A	Anti-infectives	5402	15.1%

M01A	Anti-inflammatory, non-steroids	3754 	10.5%

N02B	Other analgesics and anti-pyretics	2884 	8.1%

G03D	Progestogens	2871 	8.0%

A02A	Antacids	2683	7.5%

D07C	Corticosteroids, combinations with antibiotics	2090 	5.9%

R06A	Antihistamines for systemic use	1932 	5.4%

A03A	Drugs for functional bowel disorders	1866 	5.2%

J01D	Other beta-lactam anti-bacterials	1863 	5.5%

G03C	Estrogens	1837 	5.1%

ATC Code	Drug classification

G01A	Anti-infectives

M01A	Anti-inflammatory, non-steroids

N02B	Other analgesics and anti-pyretics

G03D	Progestogens

A02A	Antacids

D07C	Corticosteroids, combinations with antibiotics

R06A	Antihistamines for systemic use

A03A	Drugs for functional bowel disorders

J01D	Other beta-lactam anti-bacterials

G03C	Estrogens


Variables	Number	Percentage

Acute or chronic inflammation	36	30

Rheumatism 	33	26.6

Degeneration of valves	49	40.8

Endocarditic 	2	1.6

es	r	tage

Acute or chronic inflammation	36	30

Rheumatism	33	26.6

Degeneration of valves	49	40.8

Endocarditic	2	1.6


		Pairwise correlation at age 7 year

Compound	PFAS concentration, ng/mL, median (IQRa)	PFOS	PFOA	PFHxS

Age 5 year


Analyses	Nanoemulsion	Curcumin-nanoemulsion

Size (nm)	200 ± 9.9	199 ± 0.2

Zeta potential (mV)	−40.2	−46.3

Polydispersity index (PdI)	0.248	0.179

Analyses	Nanoemulsion	Curcumin-nanoemulsion

Zeta potential (mV)	−40.2	−46.3

Polydispersity index (PdI)	0.248	0.179


Indicators	Value

White blood cell	5200/μL

Hemoglobin	11.3 g/dL

Platelet	103 × 103/μL

Prothrombin time	96%

Activated partial thromboplastin time	22.6 s

Aspartate aminotransferase	26 U/L

Alanine aminotransferase	20 U/L

Lactate dehydrogenase	244 U/L

Alkaline phosphatase	280 U/L

Total bilirubin	0.7 mg/dL

Total protein	6.9 g/dL

Albumin	3.9 g/dL

Blood urea nitrogen	25.6 mg/dL

Creatinine	1.05 mg/dL

Uric acid	7.3 mg/dL

Na	139 mEq/L

K	6.9 mEq/L

Cl	104 mEq/L

Total cholesterol	169 mg/dL

C-reactive protein	0.11 mg/dL

Protein induced by vitamin K absence II	61 mAU/mL

α-Fetoprotein	384 ng/mL

Indicators

White blood cell

Hemoglobin

Platelet

Prothrombin time

Activated partial thromboplastin time

Aspartate aminotransferase

Alanine aminotransferase

Lactate dehydrogenase

Alkaline phosphatase

Total bilirubin

Total protein

Albumin

Blood urea nitrogen

Creatinine

Uric acid

Na

K

Cl

Total cholesterol

C-reactive protein

Protein induced by vitamin K absence II

α-Fetoprotein


H-reflex parameters	Ankle Positions	Muscle and posture

		Sol	MG	LG

		Lying	Standing	Lying	Standing	Lying	Standing

Amplitude	N	7.25*†(3.35)	4.28*§‡(2.03)	2.06*†(1.20)	1.38*§‡(0.85)	1.50*†(0.70)	1.15*§‡(0.67)

	DF	2.	1.	0.60†(0.39	0.53	0.47†(	0.


Genotypes	No. identified proteins	ρ-Valuea/FPRb(%)	No. proteins


Key actor	Moura-Barrancos	Guadiana	Malcata	Total

Land owners (including livestock breeders)	9	9	5	23

Local council representatives	8	8	8	24

Local nature conservation technicians (administration, NGOs, fiscalization)	6	7	7	20

Land and hunting managers	6	8	2	16

Hunting guards	8	3	3	14

Nature activity users and promoters (tourism, collectors, leisure)	6	7	5	18

Lynx observers	9	-	7	16

Total	52	42	37	131

Hunter	26	19	15	60

Non-hunter	26	23	22	71

Key actor	Moura-Barrancos	Guadiana	Malcata	Total

Land owners (including livestock breeders)	9	9	5	23

Local council representatives	8	8	8	24

Local nature conservation technicians (administration, NGOs, fiscalization)	6	7	7	20

Land and hunting managers	6	8	2	16

Hunting guards	8	3	3	14

Nature activity users and promoters (tourism, collectors, leisure)	6	7	5	18

Lynx observers	9	-	7	16

	52	42	37

Key actor	Moura-Barrancos	Guadiana	Malcata	Total

Total				131

Hunter	26	19	15	60

Non-hunter	26	23	22	71


Topic	Reference	Question	Summary of the results

Knowledge	(26–42)	Differences in knowledge	Almost all studies found a gradient in knowledge about HPV and cervical cancer with any of the variables used to measure SES or deprivation: educational level, disadvantaged groups, etc

	(43–48)	Effective tools to improve knowledge and reduce inequalities	Differences tend to diminish after any kind intervention to inform women. Results about written material are inconclusive; short counseling showed to be effective

Coverage	(16, 49–51)	Longer screening intervals can increase the coverage for hard-to-reach population	No data are available

	(9, 52)	Access to opportunistic HPV testing could be limited by the high cost of the test in private laboratories	No data are available

	(49, 53, 54)	Self-sampling device could be used to reduce sampling costs, but could affect coverage	Only one trial conducted in Mexico. A lower coverage was achieved, but it was due to women not found at home and to whom the self-sampling was not mailed

Participation	(9, 13, 16, 17, 21, 26, 32, 50, 52, 53, 55–57)	The proposal of a new test may change the participation	Several observational studies and one trial found a small increase in participation when invited for a HPV test compared to Pap test. No data on how it will impact on inequalities

		Longer intervals could disrupt the habits, thereby of women reducing participation	No data are available

	(14, 22, 49, 53–55, 58–75)	Self-sampling device could be used to participation in screening program	Nine studies showed a positive effect of self-sampling in under-screened population. Some studies showed that the device is acceptable also among disadvantage women, even in some case to a minor extent

Compliance to screening protocols	(41)	Longer intervals could increase opportunistic over-screening	No data are available

	(9, 21, 35, 36, 57)	Referral to early rescreen after HPV positive cytology-negative test could increase use of unnecessary ascertainment	No data are available

	(17, 21, 76, 77)	Referral to early rescreen after HPV positive cytology-negative test could result in substantial loss to follow up	The compliance to early rescreen in this group of women varied among studies, showing that correct communication can reduce loss to follow up. No data about differences in socio-economic status are available

Communication of positive results	(2, 9, 78–81)	Communication of HPV positivity can induce anxiety	Several studies showed anxiety after the communication of Pap test and/or HPV positivity. Women with higher educational level are advantaged in understanding the gynecologist’s and midwife’s recommendations and explanations

	(32, 40, 79, 80, 82–84)	Communication of HPV positivity can induce changes in sexual habits	Some studies showed concern about the sexual transmission of the virus. These concerns were stronger in women of lower educational level and disadvantaged ethnic groups

	(31, 36, 84–91)	Effective ways to reduce anxiety and other adverse effects	Face-to-face counseling was preferred by women, but cannot be used only for positive results because of the anxiety caused by the understanding that the test was positive and the need to wait for the counseling. Short phone counseling only for positive was also appreciated

Interaction vaccine and screening	(38, 92–98)	Negative effect of vaccine on future screening	Only one studies reported a small proportion of girls referring that vaccination would change their attitude to screening

	(56, 99–103)	Association between vaccine and screening attitudes	Several studies showed an association between vaccine and screening attitude or between vaccination and screening coverage in mothers. Results are heterogeneous


Cytogenetic abnormality	Frequency	ASXL1 mutational frequency	SETBP1 mutational frequency	SRSF2 mutational frequency	U2AF1 mutational frequency	SF3B1 mutational frequency	Spanish cytogenetic risk stratification	Mayo–French cytogenetic risk stratification

+8	~23%	~24%	0%	~27%	0%	0%	High risk	Intermediate risk

-Y	~20%	~12% (SS)	~40%	~16%	0%	~9%	Low risk	Low risk

-7/7q-	~14%	~14%	~40%	~11%	40%	0%	High risk	Intermediate risk

20q-	~8%	~10%	0%	~11%	0%	0%	Intermediate risk	Intermediate risk

der(3q)	~8%	~2% (SS)	0%	~3%	20%	45% (SS)	Intermediate risk	Low risk

+21	~8%	~10%	0%	~5%	20%	0%	Intermediate risk	Intermediate risk

Complex and monosomal karyotypes (MK)	~10%	~4%	~20%	~8%	~40% (SS)	0%	Complex high risk. MK not included in stratification	High risk

Cytogenetic abnormality	Frequency	ASXL1 mutational frequency	SETBP1 mutational frequency	SRSF2 mutational frequency	U2AF1 mutational frequency	SF3B1 mutational frequency	Spanish cytogenetic risk stratification	Mayo–French cytogenetic risk stratification

+8	~23%	~24%	0%	~27%	0%	0%	High risk	Intermediate risk

-Y	~20%	~12% (SS)	~40%	~16%	0%	~9%	Low risk	Low risk

-7/7q-	~14%	~14%	~40%	~11%	40%	0%	High risk	Intermediate risk

20q-	~8%	~10%	0%	~11%	0%	0%	Intermediate risk	Intermediate risk

der(3q)	~8	~2% (SS)			20	4	Intermediate

Cytogenetic abnormality	Frequency	ASXL1 mutational frequency	SETBP1 mutational frequency	SRSF2 mutational frequency	U2AF1 mutational frequency	SF3B1 mutational frequency	Spanish cytogenetic risk stratification	Mayo–French cytogenetic risk stratification

	%		0%	~3%	%	5% (SS)	 risk	Low risk

+21	~8%	~10%	0%	~5%	20%	0%	Intermediate risk	Intermediate risk

Complex and monosomal karyotypes (MK)	~10%	~4%	~20%	~8%	~40% (SS)	0%	Complex high risk. MK not included in stratification	High risk


Risk factor	Changes in capillary morphology or blood rheology

Aging	Human brain: Pericyte loss. Variable capillary diameters, increased capillary tortuosity, twisting, and looping. Thickened basement membranes with inclusions. Pericapillary fibrosis [29, 30]

Hypertension	Animal brain: Pericyte degeneration, swelling of endothelium and surrounding astrocyte end feet. Thickened basement membranes [31, 32]In vitro: Angiotensin II, endothelin-1 constrict retinal pericytes [33, 34]

Diabetes	Human: Thickened basement membranes [35, 36]. Hyperviscosity and reduced erythrocyte deformability in proportion to microvascular complications [37]Animal models: Pericyte loss and thickening of capillary basement membrane [31, 38, 39]. Glycocalyx degradation by oxidative stress, oxidized lipoproteins, and hyperglycemia [40–42]In vitro: Hyperglycemia-induced oxidative stress in the pericytic mitochondria causes pericyte apoptosis [43]

Alzheimer’s diseaseAPOE ε4 genotype	Human brain: Pericyte degeneration, pericapillary fibrosis [44]In vitro: Cultured human pericytes undergo degeneration when exposed to certain subtypes of Aβ [45]. Pericytes express Aβ receptors involved in amyloid internalization and pericyte death [46]

Nicotine use (including smoking)	Nicotine upregulates the expression of adhesion molecules in the capillary endothelium [47] and increases leukocyte rolling [48]

Risk factor	Changes in capillary morphology or blood rheology

Hypertension	Animal brain: Pericyte degeneration, swelling of endothelium and surrounding astrocyte end feet. Thickened basement membranes [31, 32]In vitro: Angiotensin II, endothelin-1 constrict retinal pericytes [33, 34]

Diabetes	Human: Thickened basement membranes [35, 36]. Hyperviscosity and reduced erythrocyte deformability in proportion to microvascular complications [37]Animal models: Pericyte loss and thickening of capillary basement membrane [31, 38, 39]. Glycocalyx degradation by oxidative stress, oxidized lipoproteins, and hyperglycemia [40–42]In vitro: Hyperglycemia-induced oxidative stress in the pericytic mitochondria causes pericyte apoptosis [43]

Alzheimer’s diseaseAPOE ε4 genotype	Human brain: Pericyte degeneration, pericapillary fibrosis [44]In vitro: Cultured human pericytes undergo degeneration when exposed to certain subtypes of Aβ [45]. Pericytes express Aβ receptors involved in amyloid internalization and pericyte death [46]

Nicotine use (including smoking)	Nicotine upregulates the expression of adhesion molecules in the capillary endothelium [47] and increases leukocyte rolling [48]


Authors	Contrast

*Aichorn et al., 2009	False belief > photo (question)

*Abraham et al., 2010	Belief-questions > control-questions and desire-questions > control-questions

*Bahnemann et al., 2010	ToM judgments minus appearance judgments

*Bruneau et al., 2012	ToM localizer

*Dohnel et al., 2012	Sally Anne task (true and false ToM minus reality)

Fletcher et al., 1995	ToM stories vs. Physical stories

Gallagher et al., 2000	ToM vs. non-ToM stories

Gobbini et al., 2007	False belief stories vs. physical belief stories

*Hartwright et al., 2012	False belief minus false photograph

Hynes et al., 2005	Cognitive PT minus Control

*Jenkins and Mitchell, 2010	Mentalizing scenarios > non-social scenarios

*Kobayashi et al., 2008	ToM > physical (both japanese and english language groups)

*Kobayashi et al., 2006	ToM compared with non-ToM-conjunction among language groups

*van der Meer et al., 2011	ToM high inhibition minus fixation

Mitchell, 2007	Tom minus attention cueing task

Perner et al., 2006	False belief vignettes minus photo vignettes

*Rabin et al., 2009	ToM photo minus autobiographical memory photo

Ruby and Decety, 2003	3rd person minus 1st person

*Samson et al., 2008	ToM cartoons minus non-ToM cartoons

Saxe and Kanwisher, 2003	ToM inference minus mechanical inference

Saxe and Powell, 2006	False belief minus false photograph

Saxe et al., 2006	ToM reference experiment

*Veroude et al., 2012	Others vs. self (females only)

Vollm et al., 2006	ToM minus physical causality one character

*Wolf et al., 2010	Social minus physical inference (multiple choice and silent)

Young et al., 2007	Belief minus photo

*Young et al., 2010	Mental > physical sentences

*Zaitchik et al., 2010	Belief sentences > control sentences


Maternal health service use indicator	Overall (n = 1457)	District	P value

Jhelum (n = 747)	Layyah (n = 710)

Sought at least one antenatal care (ANC) visit	96.6	97.8	95.3	0.01

Type of ANC provider

 Community Midwife (CMW)	8.3	13.8	2.4	0.00

 Doctor	57.5	57.2	57.8	0.83

 Skilled birth attendant	27.2	24.3	30.4	0.02

 Dai	4.6	2.6	6.7	0.00

Type of childbirth attendant

 CMW	7.9	12.4	3.2	0.00

 Doctor	36.1	47.6	24	0.00

 Non-physician skilled birth attendant	25.5	26.3	24.6	0.49

 Dai/traditional birth attendant	30.5	13.7	48.2	0.00

Place of delivery

 Home (home and dai home)	41.2	29.3	54	0.00

 CMW clinic/home	1.1	3.1	0.7	0.01

 Government	21.6	27.1	15.9	0.00

 Private	35.1	40.5	29.4	0.00

Satisfaction with CMW care

For ANC (n = 245)				0.05

 Very satisfied	39.5	44.2	12.9

 Satisfied	53.7	50.0	74.2

 Somewhat satisfied	2.9	1.8	9.6

 Somewhat dissatisfied/dissatisfied	4.0	4.0	3.3

For delivery (competency) (n = 109)				0.00

 Very satisfied	68.1	75.2	39.3

 Satisfied	28.5	21.1	58.5

 Somewhat satisfied	1.7	1.6	2.2

 Somewhat dissatisfied/dissatisfied	1.7	2.2	0.0


	High-energy probe	Low-energy probe	Units

Source used	22Na	99mTc

Photon energy	511	142	keV

Sensitivity	10	12	cps/kBq

Spatial resolution

 @ 1 cm in air	15	10	mm

 @ 5 cm in air	47	35	mm

Count rate range	1–50	1–100	kcps

Count rate loss	< 10%	< 10%

Shielding	n.a.	1	mmPb

Weight	500	650	g

	High-energy probe	Low-energy probe	Units

Shielding	n.a.	1	mmPb

Weight	500	650	g


Data	Feature	Vector	Algorithm	F1	AUC	p-value

iDASH	Bag-of-words + UMLS (5SG)	Tf-idf	SVM-Lin	0.932	0.957	<0.01

	Bag-of-words + UMLS (All)	Tf-idf	SVM-Lin	0.931	0.957	<0.01

	Bag-of-words + UMLS (15ST)	Tf-idf	SVM-Lin	0.930	0.957	<0.01

	Bag-of-words + UMLS (All)	Tf-idf	SVM-Lin-SGD	0.928	0.955	<0.01

	Bag-of-words	Tf-idf	SVM-Lin	0.927	0.955	<0.01

	Bag-of-words	Tf	NB	0.893	0.935	Baseline

MGH	Bag-of-words + UMLS (5SG)	Tf-idf	SVM-Lin	0.934	0.964	<0.01

	Bag-of-words + UMLS (15ST)	Tf-idf	SVM-Lin	0.931	0.962	<0.01

	Bag-of-words + UMLS (All)	Tf-idf	SVM-Lin	0.930	0.962	<0.01

	Bag-of-words	Tf-idf	SVM-Lin	0.924	0.958	<0.01

	Bag-of-words + UMLS (5SG)	Tf	LR-L1	0.915	0.953	<0.01

	Bag-of-words	Tf	NB	0.755	0.867	Baseline

Data	Feature	Vector

iDASH	Bag-of-words + UMLS (5SG)	Tf-idf

	Bag-of-words + UMLS (All)	Tf-idf

	Bag-of-words + UMLS (15ST)	Tf-idf

	Bag-of-words + UMLS (All)	Tf-idf

	Bag-of-words	Tf-idf

	Bag-of-words	Tf

MGH	Bag-of-words + UMLS (5SG)	Tf-idf

	Bag-of-words + UMLS (15ST)	Tf-idf

	Bag-of-words + UMLS (All)	Tf-idf

	Bag-of-words	Tf-idf

	Bag-of-words + UMLS (5SG)	Tf

	Bag-of-words	Tf


Characteristic	Number (N = 1,568)	Percent (%)

Sex	915	58.4

Female	653	41.6

Male

Age group (in years)

15 – 24	410	26.1

25 – 34	595	37.9

35 – 49	563	35.9

Educational level

No formal education	142	9.1

Primary Education	1,308	83.4

Secondary Education and above	118	7.5

Marital status

Married/cohabiting	969	62.2

Single	444	27.7

Divorced/separated/widowed	155	10.1

Occupation

Student	56	3.6

Salaried employed	36	2.3

Self-employed	76	4.8

Peasant/farmer	1,370	87.4

Others	30	1.9

Radio ownership

Yes	1,211	77.2

No	357	22.8

Characteristic	Number (N = 1,568)	Percent (%)

Sex	915	58.4

Female	653	41.6

Male

Age group (in years)

15 – 24	410	26.1

25 – 34	595	37.9

35 – 49	563	35.9

Educational level

No formal education	142	9.1

Primary Education	1,308	83.4

Secondary Education and above	118	7.5

Marital status

Married/coh	96	62.2

abiting	9

Single	444	27.7

Divorced/separated/widowed	155	10.1

Occupation

Student	56	3.6

Salaried employed	36	2.3

Self-employed	76	4.8

Peasant/farmer	1,370	87.4

Others	30	1.9

Radio ownership

Yes	1,211	77.2

No	357	22.8


CKMB peak (iu/l)	205 ± 138	346 ± 239	0.004

Angiography

Non obstructive	5 (8%)	1 (3%)

One vessel disease	34 (51%)	10 (35%)

Multivessel disease	22 (33%)	15 (52%)

Not done	5 (8%)	3 (10%)	0.31


Group session topics

Session #	Physical activity	Nutrition	Educational incentive

1	Overview of healthy nutrition	Overview of exercise	Pedometer

2	Eating healthy on a budget	Being active at home	Fruit and vegetable guide

3	Eating out and fast food	Local exercise resources	Water bottle

4	Portion control and measuring	Hidden times for exercise	Measuring cups

5	Label reading and breakfast	Injury prevention and treatment	Massage tool

6	Healthy drinks	Building strong muscles	Healthy drink ingredients

7	Mindful eating and lunch	Take a deep breath and relax	Muscle relaxation CD

8	Healthy fast food and dinner	Exercise with friends and family	Whole grain pasta

9	Eating at social events and holidays	Mini holidays for exercise	Food pamphlet

10	Healthier traditions and review	Review and social dancing	Recipe with ingredients

11	Relapse response	Review and relay games	Motivational letter

12-15	Review relapse response, problem solving, and goal setting	Social support cards and displayable health guides

<underline>Community health worker support session topics*</underline>

<underline>Nutrition</underline>

 Beverage inventory, evaluation of milk and water consumption, and goal for healthy beverages

 Evaluation of fat in cooking and goal for cooking with less fat (steaming, baking, etc.)

 Evaluation of fruit and vegetable consumption and goal for consuming more fruits and vegetables

 Evaluation of high calorie foods and goals for reduction of high calorie food or snacking

 Decision-making for shopping and meal planning

<underline>Physical activity</underline>

 Chart and practice walking route (at first environmental support session)

 Identify support network of friends and family members for exercise

 Identify exercise locations in and around home

 Select physical activity goal

 Identify new physical activities to try

*Topics may be covered in any order, but must be during the intensive intervention phase.

Group session topics

Session #	Physical activity	Nutrition	Educational incentive

1	Overview of healthy nutrition	Overview of exercise	Pedometer

2	Eating healthy on a budget	Being active at home	Fruit and vegetable guide

3	Eating out and fast food	Local exercise resources	Water bottle

4	Portion control and measuring	Hidden times for exercise	Measuring cups

5	Label reading and breakfast	Injury prevention and treatment	Massage tool

6	Healthy drinks	Building strong muscles	Healthy drink ingredients

7	Mindful eating and lunch	Take a deep breath and relax	Muscle relaxation CD

8	Healthy fast food and dinner	Exercise with friends and family	Whole grain pasta

9	Eating at social events and holidays	Mini holidays for exercise	Food pamphlet

10	Healthier traditions and review	Review and social dancing	Recipe with ingredients

11	Relapse response	Review and relay games	Motivational letter

12-15	Review relapse response, problem solving, and goal setting	Social support cards and displayable health guides

Community health worker support session topics*

Nutrition

Beverage inventory, evaluation of milk and water consumption, and goal for healthy beverages

Evaluation of fat in cooking and goal for cooking with less fat (steaming, baking, etc.)

Evaluation of fruit and vegetable consumption and goal for consuming more fruits and vegetables

Evaluation of high calorie foods and goals for reduction of high calorie food or snacking

Decision-making for shopping and meal planning

Physical activity

Chart and practice walking route (at first environmental support session)


Feature	P. fici

Assembly size (Mb)	52

Scaffold N50 (Mb)	4

Coverage (fold)	24.5

GC content (%)	48.73

GC exon (%)	53.56

GC intron (%)	44.18

Repeat content (%)	2.97

Protein-coding genes	15,413

Gene density (genes per Mb)	296.9

Exons per gene	2.76

tRNA genes	258

rRNA genes	52

Pseudogenes	494

Transposable elements (%)	1.54


	Controls (N = 39) (%)	Cases (N = 123) %

Stage I	22 (56)	55 (45)

Stage II	14 (36)	54 (44)

Stage III	3 (8)	14 (11)

ER or PR positive/HER2 negative	33 (85)	104 (85)

ER or PR positive/HER2 positive	6 (15)	19 (15)

	Controls (N = 39) (%)	Cases (N = 123) %

ER or PR positive/HER2 positive	6 (15)	19 (15)


Mutation model	Sign test	Standardized differences test	Wilcoxon test

IAM	Hee = 20.49	T2 = 13.196	P (one tail for H deficiency) 1.000

	Hd = 0	P = 0.000	P (one tail for H excess) 0.000

	He = 40		P (two tails for H excess and deficiency) 0.000

	P = 0.000

SMM	Hee = 22.40	T2 = 11.518	P (one tail for H deficiency) 1.000

	Hd = 0	P = 0.000	P (one tail for H excess) 0.000

	He = 40		P (two tails for H excess and deficiency) 0.000

	P = 0.000

Mutation model	Sign test	Standardized differences test	Wilcoxon test

	P = 0.000

SMM	Hee = 22.40	T2 = 11.518	P (one tail for H deficiency) 1.000

	Hd = 0	P = 0.000	P (one tail for H excess) 0.000

	He = 40		P (two tails for H excess and deficiency) 0.000

	P = 0.000


Substrate	Enzymatic activity(mU/μL)

Laminarin	0.049 ± 0.002

CMC	0.010 ± 0.001

Pectin	0.0008 ± 0.0001

Xylan	0.034 ± 0.002

pnPβGlu	0.020 ± 0.001

pnPβXyl	0.013 ± 0.001

Avicel	0.015 ± 0.001

CSCB	0.032 ± 0.002


Parameters	Units

TS a	% FM d

VS b	% TS

COD c	g·L−1

C	% TS

N	% TS

P	% TS

S	% TS

Ca	mg·L−1

Na	mg·L−1

K	mg·L−1

Mg	mg·L−1


Variables	Rank†	P-value	HR	95% CI

Age	5	0.60	0.9	0.5-1.6

Male	3	0.10	2.5	0.8-7.7

Black	6	0.82	1.1	0.3-3.8

Initial creatinine ≥ 175 μmol /L	1	0.00	6.1	2.2-17

Uncontrolled hypertension	2	0.01	4.3	1.4-14

Trombotic microangiopathy	4	0.19	1.9	0.7-5.2

Variables	Rank†	P-value	HR	95% CI

Uncontrolled hypertension	2	0.01	4.3	1.4-14

Trombotic microangiopathy	4	0.19	1.9	0.7-5.2


Gene locus	Control (fructose)	Xylose 1 hour	Xylose 4 hours	Xylose + glucose 1 hour	Xylose + glucose 4 hours

An06g00620	0.08 ± 0.03	0.42 ± 0.07	0.38 ± 0.05	0.003 ± 0.00	0.03 ± 0.01


Diploid, n (%)	Aneuploid, n (%)	p-value*


Container capacity, L	Number of 2MR disks	Target ppb

10	1/5	27

20	1⁄2	27

30	2/3	27

40	1	27

50	1	27

Container capacity, L

10

20

30

40

50

Number of 2MR disks	Target ppb

1/5	27

1⁄2	27

2/3	27

1	27

1	27


Variable	B	SE	p	OR

Theme B vs all others	3.260	.744	.017	4.64

having some TFA questions	2.816	.757	<.001	16.71

constant	-5.515	.841	<.001	.004

Variable	B	SE	p	OR

having some TFA questions	2.816	.757	<.001	16.71

constant	-5.515	.841	<.001	.004


A	B	C	D	E	F	S	M	Range(where present)	Peak assignments*

–	–	–	–	–	1299	–	–	1299	(CH2)n deformations

–	–	–	–	1356	–	1355	–	1356	Tertiary (CH) deformation

1411	1415	1413	1413	1413	1415	–	–	1411–1415	(CH2) or (CH3)

–	1438	–	–	–	1439	–	–	1438–1439	(CH2)

1450	–	1443	1447	1447	1449	–	1445	1443–1450	(CH2), (CH)

1509	–	1509	1507	1511	–	1510	1510	1507–1511	Asymmetrical aryl ring stretch

1603	–	1603	1603	1602	1605	–	–	1602–1605	Aryl stretching vibration

1716	1724	1729	1724	1727	1719	1727	1728	1716–1729	C = O stretch of aldehydes, ketones, esters

–	–	–	–	–	–	2820	–	2820	CH bending

–	2851	2845	2856	2856	2850	–	–	2845–2856	CH antisymmetric and symmetric stretch of aliphatic compounds

–	2882	–	–	–	2881	–	–	2881–2882	CH antisymmetric and symmetric stretch of aliphatic compounds

2905	2907	2907	2908	2907	–	–	2909	2905–2909	CH antisymmetric and symmetric stretch of aliphatic compounds

–	2932	–	–	–	2932	–	2934	2932–2934	CH antisymmetric and symmetric stretch of aliphatic compounds

2939	–	–	2941	2938	2938	2939	–	2938–2941	Antisymmetric C–H stretch in –OCH3 symmetric CH stretch

2963	2966	2966	2968	2966	2967	–	2969	2963–2969	CH antisymmetric and symmetric stretch of aliphatic compounds

3074	–	–	–	3073	–	–	–	3073–3074	(=C–H)

Range(where present)	Peak assignments*

1299	(CH2)n deformations

1356	Tertiary (CH) deformation

1411–1415	(CH2) or (CH3)

1438–1439	(CH2)

1443–1450	(CH2), (CH)

1507–1511	Asymmetrical aryl ring stretch

1602–1605	Aryl stretching vibration

1716–1729	C = O stretch of aldehydes, ketones, esters

2820	CH bending

2845–2856	CH antisymmetric and symmetric stretch of aliphatic compounds

2881–2882	CH antisymmetric and symmetric stretch of aliphatic compounds

2905–2909	CH antisymmetric and symmetric stretch of aliphatic compounds

2932–2934	CH antisymmetric and symmetric stretch of aliphatic compounds

2938–2941	Antisymmetric C–H stretch in –OCH3 symmetric CH stretch

2963–2969	CH antisymmetric and symmetric stretch of aliphatic compounds

3073–3074	(=C–H)


	6-month change score	Difference of two groups (I – C)

	Intervention Group	Control Group

N*		N*

Laboratory data

HbA1c (% (mmol/l)	224	−1.0 (−1.2 to −0.7)	217	−0.5 (−0.8 to −0.3)	−0.4 (−0.8 to −0.1)

(−10.5 (−13.2 to −8.0))		(−5.9 (−8.7 to −3.2))	(−4.6 (−8.4 to −0.9))

Social support

Social support score from Diabetes Care Profile (points)	222	0.2 (−0.0 to 0.4)	217	0.1 (−0.1 to 0.3)	0.1 (−0.2 to 0.4)

SF-12 Scores

PCS-12 (points)	203	0.6 (−0.4 to 1.6)	196	1.6 (0.6 to 2.6)	−1.0 (−2.4 to 0.4)

MCS-12 (points)	203	1.4 (0.3 to 2.5)	196	−0.2 (−1.3 to 0.9)	1.6 (0.1 to 3.2)

Program evaluation (Post-intervention only)

Participants’ perception of empowerment attributable to the program at follow-up (points) †	226	4.4 (4.4 to 4.5)	216	4.3 (4.2 to 4.4)	0.1 (0.0 to 0.2)

	6-month change score	Difference of two groups (I – C)

	Intervention Group	Control Group

N*		N*

Laboratory data

HbA1c (% (mmol/l)	224	−1.0 (−1.2 to −0.7)	217	−0.5 (−0.8 to −0.3)	−0.4 (−0.8 to −0.1)

(−10.5 (−13.2 to −8.0))		(−5.9 (−8.7 to −3.2))	(−4.6 (−8.4 to −0.9))

Social support

	22	0.	2	0.1 (−0.1 to 0.3	0.1 (−0.2 to

Social support score from Diabetes Care Profile (points)	2	2 (−0.0 to 0.4)	17	)	 0.4)

SF-12 Scores

PCS-12 (points)	203	0.6 (−0.4 to 1.6)	196	1.6 (0.6 to 2.6)	−1.0 (−2.4 to 0.4)

MCS-12 (points)	203	1.4 (0.3 to 2.5)	196	−0.2 (−1.3 to 0.9)	1.6 (0.1 to 3.2)

Program evaluation (Post-intervention only)

Participants’ perception of empowerment attributable to the program at follow-up (points) †	226	4.4 (4.4 to 4.5)	216	4.3 (4.2 to 4.4)	0.1 (0.0 to 0.2)


 	 	Value

Age (years)	 	41 (18–79)

Gender (n)	Male	64

 	Female	73

Marital status (n)	Single	26

 	Married	111

Education (n)	Primary school	69

 	Secondary school	17

 	High school	31

 	University	20


Antimicrobial Agent	Number (%) of E. coli Isolates	Test of Independencep-Value *

Adults	Young Children

n = 296	n = 86

Tetracycline	63 (21.3)	17 (19.8)	0.7610

Doxycycline	46 (15.5)	11 (12.8)	0.5287

Trimethoprim/sulfamethoxazole	33 (11.1)	12 (14)	0.4776

Chloramphenicol	18 (6.1)	0	0.0171

Nalidixic acid	39 (13.2)	8 (9.3)	0.3358

Norfloxacin	8 (2.7)	2 (2.3)	1

Ciprofloxacin	8 (2.7)	2 (2.3)	1

Nitrofurantoin	12 (4.1)	3 (3.5)	1

Antimicrobial susceptibility characteristic

R	224 (75.7)	47 (54.7)	0.0002 *

MDR	90 (30.4)	12 (14)	0.0024 *


Qualitative Theme	Exemplar Quotation(s)

Less Willing to Honestly Disclose SU/MH with PROs

 Harder to disclose to computer	“It takes a lot for a person to express how they feel when you can be face to face with somebody. Emotionally and physically...being face to face with her ... It’s easier.” (Patient 20, Not Retained, MH only)

 Fear of Provider Judgement	“Other patients see [will start] missing their appointments because they ashamed of what the doctor seen. Especially when you bring it to their attention...They’ll start shying away from the clinic” (Patient, Retained, SU only).

More Willing to Honestly Disclose SU/MH with PROs

 Easier to disclose to computer	“That would give the doctor herself an extra little something that well, I can read this and maybe they don’t want to open to me, but they’ll open up to this. So I think that’d be real good.” (Patient 19, Retained, SU only)

Qualitative Theme	Exemplar Quotation(s)

More Willing to Honestly Disclose SU/MH with PROs

Easier to disclose to computer	“That would give the doctor herself an extra little something that well, I can read this and maybe they don’t want to open to me, but they’ll open up to this. So I think that’d be real good.” (Patient 19, Retained, SU only)


Modification	Role	Species/System	Region/Residue(s) 	Enzyme	Reference(s)

Ubiquitination	Target for proteasome dependent degradation	Human Mcm10(HeLa, U2OS)in vivo	440–525783–803843–875(regions that can mediate degradation)	Cul4-DDB1-VprBP	[93,95,97,98]

Ubiquitination	Functional regulation during S-phase	Yeast Mcm10(Saccharomyces cerevisiae)	K85, K122, K319, K372, K414, K436	Not identified	[67,100]

Phosphorylation	Unknown function	Human Mcm10 (HeLa)	T85, S93, S150, S155, A182, S203, S204, A210, S212, T217, R286, T296, S488, S548, S555, S559, S577, S593, Y641, S644, T663, S706, S824(* only sites identified in more than 2 datasets are listed)	Not identified, except T85 which is ATR or ATM dependent.	[93,101,102,103,104,105,106,107,108,109,110,111,112]

Phosphorylation	Replisome stability	Xenopus extract	S154, S173, S206, S596, S630, S690, S693	S-CDK	[113]

Acetylation	Protein stability and DNA binding	Human Mcm10	K267, K312 *, K318, K390 *, K657, K664, K668, K674 *, K681 *, K682 *, K683 *, K685 *, K737 *, K739 *, K745 *, K761 *, K768 *, K783, K847 *, K849 *, K853, K868, K874	p300 (acetylase)SIRT1 * deacetylase)* indicates subset of SIRT1 target residues	[62]


	Group	n =

VAS	AR	19

	MT	20

RMQ	AR	19

	MT	20

PRI	AR	19

	MT	20